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Abstract 
 
Nanoparticulate metal-organic frameworks (MOFs) have the requisite high storage 
capacities, tailorable structures, ease of functionalisation, and excellent biocompatibilities for 
application as nanoscale drug delivery devices (DDSs). Zirconium MOFs in particular 
combine optimal stability towards hydrolysis and postsynthetic modification with low toxicity, 
and so are particularly suited for biological applications. This review covers the use of Zr 
MOFs as DDSs with focus on the different physical properties that makes them attractive for 
use. The various methods for modifying the surfaces of Zr MOFs are described with 
pertinent examples of the resulting enhancements in aqueous stability, colloidal dispersion, 
and stimuli-responsive drug release. The in vitro and in vivo application of Zr MOFs for 
photodynamic therapy and drug delivery are discussed with respect to the structural features 
of the MOFs and their surface functionality, and perspectives on their future applications and 
analogous hafnium MOFs are given.  
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1. Introduction  
 
Since it is estimated that at least one third of the population of developed countries will be 
diagnosed with cancer at some point in their lives [1], innovative and efficient cancer 
diagnosis and treatment have become major priorities for the scientific community. In this 
respect, drug delivery – the use of new technologies to selectively deliver therapeutic 
cargoes to particular areas of the body for treatment – has emerged. Drug Delivery Systems 
(DDSs) can stabilise and direct drugs to damaged tissues, minimising side effects while 
maximising treatment efficiency [2-5]. However, drawbacks such as uncontrollable drug 
release [6, 7], usually as a consequence of carrier degradation [8], or accumulation in the 
body, often due to macrophage recognition [9-12] and to low carrier degradation [13, 14], 
can hinder the clinical application of DDSs.  
 
Metal-organic frameworks (MOFs) are a new generation of materials composed of metal 
ions or clusters linked by multitopic organic ligands, forming extended network structures 
[15]. Their remarkable porosity, together with their high thermal and chemical stabilities and 
structure tailorability, makes them attractive for a wide variety of applications, including in 
healthcare [16]. MOFs offer several advantages over current DDSs, which are often purely 
organic or inorganic. The former (liposomes or polymers), although more biocompatible, 
usually present lower drug payloads [17-19], while the latter (gold, iron and silica 
nanoparticles among others), can offer notably higher drug loadings but are less 
biocompatible, and their low degradation rate can result in accumulation in the liver or 
spleen, potentially inducing unwanted side effects (Figure 1) [20-22]. 
 
 
 
Figure 1. Schematic showing the ideal properties of a MOF-based drug delivery system, using the 
structure of UiO-67, [Zr6O4(OH)4(bpdc)6]n (bpdc = 4,4’-biphenyldicarboxylate) as an example. 
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The organic/inorganic nature of MOFs has positioned them as an attractive alternative to the 
drawbacks that nanomedicine is currently facing, as it offers almost unlimited possibilities to 
design desired structures through metal-linker chemistry and postsynthetic modification in 
order to enhance their drug delivery properties, such as high drug loadings, controllable 
release of the drug, low cytotoxicity, appropriate colloidal stability and degradation rates, 
efficient cell internalisation, and anticancer cell selectivity [23-25]. As well as drug delivery, 
significant efforts have been made to interface MOFs with biological entities [26, 27], for 
example encapsulating enzymes for catalysis [28], viruses for room temperature vaccines 
[29], and even living cells [30] within MOF scaffolds. 
 
Since Ferey and co-workers reported the first study of iron-based MOFs for applications in 
biomedicine [31], a tremendous amount of work has emerged towards developing the great 
potential for various applications of nanoparticulate MOFs (NMOFs) in healthcare [16, 32-36] 
Iron MOFs are probably the most widely studied materials for healthcare applications to 
date, because iron is well tolerated, with a 50% lethal dose (LD50) of 30 gkg
-1 when orally 
administered to rats, while their high porosity enables very high drug loadings [31, 37-41]. 
Interest in zirconium-based MOFs [42] for biomedical applications has increased of late as 
zirconium is also a biocompatible metal: the human body typically contains about 300 mg of 
zirconium, and the recommended daily ingestion is 4.15 mg per day [43]. The LD50 of 
zirconyl acetate in rats, as determined by in vivo experiments, has been found to be 4.1 gkg-
1, which is lower but still comparable to iron [44]. Additionally, the hard Lewis acid/base 
coordination nature of the Zr-carboxylate bonds can render them more chemically and 
mechanically stable than iron MOFs and other high valent materials [45-47], facilitating 
postsynthetic functionalisation without compromising materials properties [48] maintaining 
excellent porosity and molecular storage capacities [49] and ultimately resulting in higher 
physiological stability [50]. In this review, we describe the various efforts to develop Zr MOFs 
as DDSs, and in biomedicine in general. The differing structures and functionalisation 
protocols for Zr MOFs are highlighted, in particular focussing on external surface 
modification and the subsequent effects on properties such as stability and dispersion. In 
vitro and in vivo applications of Zr MOFs are described in the context of structure-property 
relationships, and future research directions are discussed. 
  
5 
 
2. Structures and Syntheses of Zirconium MOFs 
 
The first Zr MOFs were reported by Lillerud et al. in 2008 [51]. The UiO series of MOFs, 
where UiO stands for Universitetet i Oslo, consists of materials where [Zr6O4(OH)4(RCO2)12] 
octahedral clusters link linear dicarboxylate ligands into extended, highly porous networks 
with overall ideal formula [Zr6O4(OH)4(L)6]n. These Zr6 clusters and derivatives serve as 
inorganic secondary building units (SBUs) in the vast majority of Zr MOFs reported to date 
[42]. 
 
The first MOF of the series, UiO-66, in which the linker is 1,4-benzene dicarboxylate (BDC), 
exhibits a pristine surface area of 1200 m2g-1 and a pore volume of 0.5 ccg-1. Its octahedral 
and tetrahedral pores have sizes of 11 and 8 Å, respectively, with pore windows of 3 and 5 Å 
[51]. A range of ligands has been used to form an isoreticular series [51-53], with porosity 
increasing with ligand length (Figure 2a) until interpenetration occurs with phenylene-bis-
ethynylbenzoate linkers [54, 55]. The use of dicarboxylate linkers with anchored pendant 
functionalities along with the excellent chemical stabilities of the series has allowed various 
postsynthetic modification (PSM) protocols to be developed to include diverse functionality 
[48, 52, 56]. Zirconium MOFs containing tricarboxylate or tetracarboxylate linkers have also 
been synthesised. For example, planar tetracarboxylates (Figure 2b) such as tetrakis(4-
carboxyphenyl)porphyrin (TCPP), when combined with 12-connected hexagonal Zr6 SBUs 
gives PCN-223 and with 6-connected Zr6 SBUs gives PCN-224; in these cases, additives to 
syntheses tune the formation of the different MOFs [57, 58]. Similarly, the structurally related 
1,3,6,8(tetrakis(p-benzoate)pyrene ligand, when linked by 8-connected Zr6 SBUs, leads to 
both NU-901 and NU-1000 MOFs [59-61]. Zr MOFs are robust enough to allow incorporation 
of multiple related ligands into the same topology – the so-called mixed linker approach – 
and also doping of alternative metal cations in place of the Zr4+ units. As such, a wide variety 
of other Zr MOFs are known [42], but this review shall focus on the above examples (Figure 
2c), which have been used in biomedicinal applications. 
 
The synthesis of Zr MOFs is usually carried out under solvothermal conditions [62-66], 
although other synthetic routes have also been reported [42, 67-69]. Solvothermal synthesis 
is sensitive to several factors, such as pH, concentration, temperature, pressure, reaction 
time, and stoichiometry, among others, which can be tuned to adjust the crystallisation 
process and obtain MOFs of various sizes. The coordination modulation protocol, first 
reported by Fischer and co-workers for Zn MOFs [70], in which monodentate ligands 
(modulators) with similar chemical functionality to the multidentate organic linkers are 
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introduced to the synthetic process, has been widely adopted as a tool to control size and 
enhance properties such as crystallinity and porosity in Zr MOFs [42, 63]. 
 
 
 
Figure 2. Chemical structures of a) dicarboxylate ligands incorporated into UiO-66 topology MOFs 
and b) tetracarboxylate ligands incorporated into Zr MOFs. c) Packing diagrams derived from crystal 
structures of classes of Zr MOFs discussed in this review. 
 
In this process, the monotopic ligands compete with the multitopic bridging MOF linkers for 
the metal coordination sites during crystallization, typically enhancing crystallinity, and acting 
in two different ways. On the one hand, if the modulator acts as a crystal growth promoter, 
the size of the crystal will depend on its concentration during synthesis [63, 66, 71]. On the 
other hand, if it acts as capping agent, its functionality can be confined to the surface, being 
permanently coordinated to metal sites and thus inhibiting crystal growth (Figure 3a) [72-74]. 
Therefore, this technique can be wisely used to control not only the particle size of the MOFs 
– scaling down the size of DDSs to <200 nm is imperative for intravenous administration in 
order to ensure unhindered circulation around small capillaries [75] – but also the surface 
chemistry during the synthetic process. Modulators can also induce missing linker and 
missing cluster defects in Zr MOFs, by capping SBUs and replacing multidentate ligands 
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throughout the bulk of the material, with a close correlation observed between modulator pKa 
and defect induction [76]. Defects can modify a number of physical properties, including 
porosity, and chemical and mechanical stability (Figure 3b) [77]. 
 
 
 
Figure 3. The effect of coordination modulation on the synthesis of UiO-66. a) PXRD patterns when 
benzoic acid is used as a modulator, showing increases in crystallinity. Scanning electron microscopy 
(SEM) images of UiO-66 prepared with b) 0 equivalents, c) 10 equivalents, and d) 30 equivalents of 
benzoic acid modulator, showing particle size control. Modified with permission from ref [63] copyright 
(2016) John Wiley and Sons. e) Increases in Brunauer–Emmett–Teller (BET) surface areas calculated 
from N2 adsorption isotherms for modulated UiO-66, with decreasing modulator pKa inducing a greater 
number of defects and thus higher surface area. Defect-free UiO-66 is expected to have a BET 
surface area of ~1200 m
2
g
–1
. Modified with permission from ref [76] copyright (2016) American 
Chemical Society. 
 
Using modulators in the synthesis of Zr MOFs is now commonplace, with many groups 
exploiting the control of particle size and surface chemistry it facilitates [42]. 
  
8 
 
3. Surface Functionalisation of Zirconium MOFs 
 
The surface chemistry of a given DDS governs its interaction with the media, improving 
stability and dispersion, and potentially allowing the drug to cross physiological barriers while 
providing the possibility of targeted carriers. As such, surface modification is of great interest 
for the development of efficient MOF-based DDSs, however, the multiple synthetic steps – 
synthesis, drug loading and surface modification – and the requirement for orthogonality 
between them, can hinder their efficient manufacture. Surface modification of MOFs [56] can 
be performed during synthesis, by the coordination modulation (CM) protocol as described 
above, or postsynthetically (PS). Postsynthetic surface modification can be categorised into 
(i) coordinative PSM, whereby the coordination chemistry of metal clusters at the particle 
surface is used to attach functionality, for example by surface ligand exchange, or (ii) 
covalent PSM, usually performed using the linker functionality as a platform for further 
reactions, such as click chemistry.  
 
Characterisation of the chemistry at the external surfaces of MOFs is complicated by the 
surface comprising a small fraction of the bulk material, although general guidelines can be 
followed. Nuclear magnetic resonance (NMR) spectroscopy of digested samples can give 
insights into the composition of the sample; the molar ratio of surface components compared 
to the linker can be estimated based on the intensities of resonances assigned to protons of 
both the linker and surface reagents, although defectivity hampers efforts to obtain mass 
fractions of surface functionality. Thermogravimetric analysis (TGA) can provide information 
on the gravimetric content and nature of the coating. If new mass loss events are observed 
at a higher temperature than those of free surface reagents, coordinative attachment to the 
Zr positions rather than electrostatic or Van der Waals forces (physisorption) is suggested. 
Similarly, the shifting of characteristic signals in Fourier transform infrared (FT-IR) spectra 
resulting from the coordination of surface reagents, and/or appearance of new signals 
corresponding to coordination bonds between Zr and surface reagents, indicate attachment 
through coordination. Porosity should not be significantly affected by surface 
functionalisation, although addition of mass at the surfaces may result in lower gravimetric 
gas uptake and surface areas. If the modified MOF has much lower porosity (or is non-
porous), it is an indication that the surface reagents are also coordinated in the inner porosity 
or simply stored in the pores as guests. Additionally, large surface units such as polymers 
may block pores or induce new features in isotherms due to kinetic effects. Dynamic light 
scattering (DLS) and zeta potential measurements can give information on changes in size, 
dispersion and surface chemistry in solution. In the solid state, scanning electron microscopy 
(SEM) may also show the physical effects of surface modification – large polymers may 
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induce “rounding” at particle surfaces – while energy-dispersive X-ray spectroscopy (EDX) 
and photoelectron spectroscopy (XPS) can give chemical information. It is important to note 
that in order to confirm surface coating content and mode, the correlation of a number of 
techniques is required. 
 
 
3.1 Coordination Modulation 
 
Examples of surface modification of Zr MOFs performed during the synthetic process are 
quite limited, despite the possibility of one-pot syntheses of functionalised nanoparticles. We 
have developed versatile and reproducible protocols based on coordination modulation [73]. 
Introducing functionalised monocarboxylic acids as modulators, for example p-azidomethyl 
benzoic acid (L1) or p-propargyloxy benzoic acid (L2), during synthesis results in their 
attachment at surface and defect sites, providing surface-coated MOFs ready for further 
functionalisation by “click” chemistry. This procedure is also compatible with the anticancer 
metabolic probe molecule, dichloroacetic acid (DCA), being used as a co-modulator of UiO-
66, resulting in the formation of well dispersed nanoparticles containing both the anticancer 
drug (~20% w/w) and the functionalised modulator. Extending the protocol to isoreticular Zr 
MOFs – including UiO-66 and its bromo, amino and nitro derivatives, and extended 
structures DUT-52 and UiO-67 – results in ~100 nm particles of DCA@UiO-66 derivatives 
and microcrystals of DCA@DUT-52 and DCA@UiO-67 when ZrCl4 is the metal precursor, 
and mesoporous <20 nm DCA@UiO-66 derivatives and ~200 nm DCA@DUT-52 and 
DCA@UiO-67 when ZrOCl2 is used as the metal precursor. The high porosity of the DCA 
modulated samples, due to DCA attachment to the inner and outer surface at defect sites 
(~20% w/w), allowed the loading of a second drug, the well-known anticancer drug 5-
fluorouracil (5-FU), into the pores of the isoreticular MOFs to create dual DDSs [78]. 
 
In principle, any carboxylate-containing molecule can act as a modulator of Zr MOFs, and 
we have also coordination modulation to introduce the biomolecules folic acid and biotin to 
the surfaces of UiO-66, with or without DCA as co-modulator, during the synthetic process 
[74]. Folic acid, in particular, could be incorporated in quantities up to 28% w/w, likely as it 
contains multiple carboxylate units, potentially acting as a linker (the so-called mixed-linker 
approach) as well as a surface ligand (Figure 4). However, the length mismatch between 
folic acid and BDC will result in significant defectivity in the resulting material. 
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Figure 4. Schematic synthesis of UiO-66 modulated by dichloroacetic acid and folic acid, showing 
incorporation of both modulators at defect and surface sites. 
 
Utilising modulators with more than one carboxylate unit results in incorporation throughout 
the structure; if there is a size mismatch with the linker, this presumably occurs at defect 
sites and coordinated to Zr6 clusters, as well as at the surface. This approach serves to trap 
the functional modulator within the structure, a method that has been exploited to prepare 
agents for photodynamic therapy (PDT). Zn-DTPP-I2@UiO-66, where DTPP-I2 is the bis-
iodo, bis-carboxy porphyrin di(4-carboxyphenyl)-10,20-bis(4-Iodophenyl)porphine, was 
prepared in a one-pot synthesis containing both BDC and Zn-DTPP-I2 [79]. The resultant 
MOF contains 1.4% w/w of porphyrin linker, as determined by inductively coupled plasma 
optical emission spectrometry (ICP-OES), which is well-distributed across ~100 nm 
nanoparticles, as determined by energy-dispersive X-ray (EDX) spectroscopic mapping. As 
the porphyrin is considerably longer than the BDC linker, it is likely incorporation occurs at 
defect sites throughout the MOF; the authors demonstrated that carboxylates are essential 
for the porphyrin linker incorporation, as a control one-pot synthesis performed with 
porphyrin with esters in the place of carboxylates, together with UiO-66 starting materials, 
resulted in no porphyrin linker incorporation, suggesting attachment through carboxylate 
units rather than pore localisation. Zn-DTPP-I2@UiO-66 was found to be porous (SBET = 901 
m2g-1) albeit with a lower surface area than expected for pristine UiO-66 (SBET ~1200 m
2g-1). 
Controls in which the porphyrin linker was introduced postsynthetically showed only 0.06% 
w/w incorporation, likely as surface decoration.  
 
Dong et al. used a similar strategy to prepare TCCP@UiO-66, with incorporation of 2.9% 
w/w of the porphyrin estimated by UV/Vis spectroscopy, and with good porosity (SBET = 1051 
m2g-1) [80]. The higher porphyrin loading compared to Zn-DTPP-I2@UiO-66 could be 
attributed to the additional carboxylate groups of TCCP (four) compared to Zn-DTPP-I2 (two) 
promoting incorporation and coordination to Zr6 clusters. Other groups have prepared this 
material as a control sample, with similar results. Park et al. have taken a similar approach to 
prepare their own sample of TCCP@UiO-66 as well as incorporating a photoswitchable, 
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dicarboxylato dithienylethene molecule, 1,2-bis(5-(4-carboxyphenyl)-2-methylthien-3-
yl)cyclopent-1-ene (BCDTE) in a range of ratios to form BCDTE@UiO-66, again for PDT 
[81]. A UiO-68 derivative, where the linker, 4,4’-(9,10-anthracenediyl)benzoic acid, is an 
annihilator was prepared containing a palladium porphyrin, Pd(II)-TCPP, used as a 
photosensitiser, in a similar synthesis. Self-assembly of Pd(II)-TCPP@UiO-68 could be fine-
tuned to modify the ratio of linker to photosensitizer in the structure by varying their ratio 
during synthesis. The MOF was used for triplet-triplet annihilation upconversion (TTA-UC)-
based imaging, and the MOF with the highest content of Pd(II)-TCPP was the most efficient 
in the TTA-UC process, as determined by luminescence spectra [82]. 
 
These examples illustrate the potential of coordination modulation for MOF-based DDSs, 
with the possibility of size and surface chemistry control exercised by multiple modulators, as 
well as using drug molecules as modulators to ensure their high loading. Multitopic 
modulators raise the prospect of defect encapsulation of functional molecules. 
 
 
3.2. Postsynthetic Coordination 
 
Zirconium MOFs can be functionalised through coordination of moieties to Zr6 SBUs; 
nucleophilic functional groups such as carboxylates [83], phosphates [84], imidazoles [85], 
and thiols[80], among others have been used to confine functionalities to the surfaces of pre-
formed Zr MOFs (Figure 5a). This mode of PSM typically requires size selectivity in order to 
address only the outer MOF surface, as if the reagents can penetrate the porosity, the inner 
surface of the MOF can also be functionalised during the process. The new surface reagent 
may coordinate to unsaturated Zr SBUs or displace surface linkers in a process that has also 
been termed surface ligand exchange (SLE). Examples are listed in Table 1. 
 
Wang et al. have shown that a carboxyl-functionalised diiodo-substituded BODIPY (I2-BDP) 
can be postsynthetically incorporated onto the surfaces of UiO-66, by heating the two in N,N-
dimethylformamide (DMF) at 65 °C for 24 h, without compromising the topology or porosity 
of the crystal [86]. The optical properties of the BODIPY functionality led to the MOF being 
studied for photodynamic therapy (PDT) and thus it was termed UiO-PDT. Comprehensive 
characterisation showed that the content of I2-BDP in the 70 nm nanoparticles of UiO-66-
PDT was around 30% w/w, with the measured BET surface area of 1422 m2g-1 confirming 
the anchoring of I2-BDP at the external surfaces rather than loading in the pores.  
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Table 1. Examples of Zirconium MOFs functionalised by postsynthetic surface coordination. 
MOF 
Surface 
Coating 
Modification 
Protocol 
Drugs Name During Review 
Enhanced 
Properties 
Ref 
UiO-66 I2-BDP 
PS carboxylate 
coordination 
Linker singlet 
oxygen 
generation 
UiO-PDT 
Cell 
internalisation; 
Cytotoxicity 
[86] 
UiO-66 
Heparin (Hep) 
Folic acid (FA) 
Biotin (Biot) 
SLE 
Dichloroacetic 
acid (DCA)  
UiO-66-Hep (PS) 
UiO-66-FA (PS) 
UiO-66-Biot (PS) 
Dispersion; 
Stability; 
Cell uptake 
[74] 
PCN-224 Folic acid (FA) 
PS carboxylate 
coordination 
Linker singlet 
oxygen 
generation 
PCN-224-FA 
Drug release; 
Cell uptake; 
Therapeutic 
efficiency 
[83] 
UiO-66 
Flavin 
mononucleotide 
(FMN) 
PS phosphate 
coordination 
Alendronate 
(AL) 
AL-UiO-66-FMN 
pH-responsive 
drug release; 
Cytotoxicity 
[84] 
UiO-68-
NH2 
SiRNA 
PS phosphate 
coordination 
Cis-platin SiRNA@UiO-Cis 
Dispersion; 
Cell uptake; 
Gene silencing; 
Overcome cis-
platin resistance 
[87] 
UiO-66 
UiO-67 
BUT-30 
1,2-dioleosyl-sn-
glycero-3-
phosphate 
(L-DOPA) 
PS phosphate 
coordination 
- 
DOPA-UiO-66 
DOPA-UiO-67 
DOPA-BUT-30 
Dispersion [88] 
PCN-223 
Phospholipid 
bilayers (PBLs) 
DOPC/DOPC 
1. PS phosphate 
coordination  
2. Self-assembly 
Linker singlet 
oxygen 
generation 
PCN-223@DOPC 
PCN-223@DOPC/DOPC 
Stability towards 
phosphate; 
Dispersion; 
Intracellular bio 
stability 
[90] 
Zr-fum 
His-tagged 
peptides 
PS imidazole 
coordination 
Pro-apoptosis 
peptides 
Zr-fum-peptide 
Cell uptake; 
Cytotoxic effect 
[85] 
UiO-66 TPP-SH 
PS thiol 
coordination 
Linker singlet 
oxygen 
generation 
UiO-66-TPP-SH 
Cell 
internalisation; 
Cytotoxicity 
[74] 
 
We have recently reported the use of surface ligand exchange (SLE) for the direct 
postsynthetic coordination of biomolecules to UiO-66 zirconium units [74]. Postsynthetic 
coordination of heparin (an anticoagulant containing sulfate coordinating groups), folic acid 
(a cancer targeting unit containing two carboxylic acid groups) and biotin (a vitamin with wide 
uses in biomedicine, which possess one carboxylic acid group) to the surfaces of UiO-66 
nanoparticles, which had first been addressed with an azide functionalised carboxylate-
containing modulator (L1) during synthesis using the coordination modulation process, is 
facile [73]. Coordination was proven to occur on the outer surface without major pore 
blockage (as determined by N2 adsorption and desorption experiments) displacing the 
modulator anchored to zirconium SBUs present on the outer surface, and yielding UiO-66-
FA (PS), UiO-66-Biot (PS) and UiO-66-Hep (PS), where PS stands for postsynthetic. PCN-
224 has been also coated with folic acid through postsynthetic coordination chemistry, in 
order to study the targeting properties of the material, PCN-224-FA, when applied to PDT, 
as the porphyrin linker has intrinsic optical properties [83]. 
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In 2014, Lin and Shi independently reported the use of phosphate groups to coordinate 
biomolecules to the available zirconium clusters on the surfaces of MOFs [84, 87]. Shi et al. 
took advantage of the affinity of the Zr SBUs of UiO-66 for phosphates to attach the amino-
biphosphonate drug Alendronate (AL) for the treatment of bone cancer. The resultant MOF, 
AL-UiO-66, had very high drug loadings (51.4% w/w) [84]. The sample was fully 
characterised and showed a drastic decrease in porosity after loading, while FT-IR spectra 
showed shifting of characteristic vibration bands for AL and new signals attributed to P-O-Zr 
stretching. The combination of the results suggests that AL was coordinated to the Zr 
positions in the outer and inner surface of the MOF, which was confirmed by O1s XPS 
spectra of the materials, explaining the high drug payloads as a consequence of the high 
affinity of the Zr6 clusters for towards AL. The authors also functionalised the surface of UiO-
66 with fluorescent flavin mononucleotide (FMN, the phosphorylated form of vitamin B2) 
using the same principle, thus forming UiO-66-FMN, which was used to explore intracellular 
imaging. The difference in size of flavin mononucleotide compared to alendronate ensured 
that the flavin was confined to the surface as it could not penetrate the porosity. 
 
Lin and co-workers studied the attachment of small interfering RNA (siRNA), through the 
phosphate groups present on its backbone, to the Zr4+ cations on the surface of UiO-68-NH2 
after loading the pores with a cis-platin prodrug. The authors further used this highly 
specialised MOF, named siRNA-UiO-Cis, for siRNA and cis-platin co-delivery [87]. Later, 
Mirkin and co-workers studied the use of phosphate coordinating groups in order to 
functionalise the surface of three different zirconium MOFs, UiO-66, UiO-67, and BUT-30 (in 
the latter (4,4ʹ-ethylene-1,2-diyl)dibenzoic acid is the MOF linker), with a phospholipid 
through PSM [88]. Importantly, in this isoreticular family of MOFs the density of zirconium 
clusters present at the surface decreases as the length of organic linker increases, and thus 
the content of 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), determined by ICP-MS, is 
higher for DOPA-UiO-66 and lower for DOPA-BUT-30. Similarly, the surface selectivity of 
the functionalisation, driven by the size of the DOPA units, was confirmed when smaller 
DOPA-functionalised nanoparticles of each MOF, in which the surface to bulk ratio is higher, 
have higher DOPA content. In other words, it was found that DOPA density correlates with 
the density of metal nodes in the outer surface. The samples were fully characterised, 
showing that after DOPA functionalisation the MOFs maintained their porosity, with FT-IR 
shifts again suggesting Zr-O-P coordination. 
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Figure 5. a) Examples of chemical structures of reagents with differing coordination units that have 
been incorporated onto the surfaces of Zr MOFs by postsynthetic coordination. b) Scheme illustrating 
a general strategy for coordination of DNA to the surfaces of Zr MOFs through terminal phosphate 
groups. Modified with permission from ref [89] copyright (2017) American Chemical Society. 
 
This protocol was later extended by Mirkin et al. into a general procedure for functionalising 
Zr MOFs with oligonucleotides through phosphate coordination (Figure 5b) [89]. A number of 
Zr MOFs with different topologies and connectivity were examined, and a correlation was 
again found between surface SBU density and surface oligonucleotide coverage. The 
connectivity of the Zr SBU also mediates surface coverage; MOFs with more highly 
connected clusters have more surface defects due to coordinative unsaturation, allowing 
greater binding of surface phosphates. The oligonucleotide coating was used to hybridise 
UiO-66 with gold nanoparticles through self-assembly of complementary DNA strands. 
 
The zirconium-phosphate interaction has also been exploited for the synthesis of Zr-based 
MOFs grafted with phospholipid bilayers (PBLs) [90]. In this case, the porphyrinic MOF PCN-
223 was synthesised by triethylamine (TEA) modulation, where variation of the quantity of 
TEA and acetic acid added to the MOF synthesis achieves particle size-control. PSM of 
PCN-223 with 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) was carried out first in 
CHCl3 in order to create a monolayer via coordination, forming nanoPCN-223@DOPC, 
which was further coated with cholesterol and DOPC, creating a hydrophobic system in 
which coated MOFs and DOPC chains self-assemble into supported MOF-PBLs, so called 
nanoPCN-223@DOPC/DOPC. The formation of PBLs was confirmed by negative staining 
with uranyl acetate, due to strong interaction between phosphate and uranyl groups, among 
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other characterisation techniques such as FT-IR spectroscopy, zeta potential measurement 
and X-ray photoelectron spectroscopy (XPS) [91]. 
 
Besides phosphate groups, the use of imidazole coordinating agents has recently been 
reported for the UiO-66 series MOF linked by the endogenous ligand fumarate, so-called Zr-
fum, also reported as MOF-801 [85]. Once more, the use of a Lewis base, in this case the 
imidazole groups present in terminal oligohistidine sequences (His-tags) of several peptide, 
was used to decorate Zr-MOFs surface with biomolecules. The strength of peptide binding to 
the MOF increased with the number of histidine residues in the peptide, and thus the authors 
used a series of peptides containing six histidine residues (H6-Tags) to coat the surface of 
Zr-fum with a range of bioactive molecules.  
 
A thiol functionalised porphyrin, 5-(4-(S-ethylthiolester)thiocarbonylphenyl)-10,15,20-tris(4-
chlorophenyl)-porphyrin (TPP-SH), has been coordinated to the surface of UiO-66 (140 nm), 
by immersion of the MOF in a dichloromethane solution of TPP-SH to generate UiO-66-TPP-
SH. Porphyrin loading was found to be 3.2% w/w, determined by UV/Vis spectroscopy, and 
loading of the thiol functionalised porphyrin was found to be much more efficient than loading 
the analogous monocarboxylate porphyrin, suggesting the thiol group is an effective 
anchoring unit [80]. 
 
 
3.3 Postsynthetic Covalent Modification 
 
Surface functionalisation can also be achieved through covalent postsynthetic modification, 
through chemical transformation of pendant functionalised groups present in the organic 
linkers of MOFs (Table 2). MOFs linked by 2-aminoterephthalic acid have long been utilised 
for postsynthetic modification through reaction at the amine moiety, with UiO-66-NH2 being a 
prime example [52, 53]. Poly(N-isopropylacrylamide) (PNIPAM) chains have been attached 
to the amino groups present in UiO-66-NH2 through amide coupling with polymer chains 
terminated with activated N-hydroxysuccinimide (NHS) esters (Figure 6a), forming the 
surface functionalised UiO-66-PNIPAM, as the polymer chains are too large to penetrate the 
porosity [92]. 
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Figure 6. Postsynthetic covalent modification of a) UiO-66-NH2 with PNIPAM through NHS-mediated 
amide coupling, b) Zr-fum with galactosylamine through EDC-mediated amide coupling with terminal 
carboxylates, and c) UiO-66-N3 with DNA by strain-promoted azide-alkyne cycloaddition. 
 
Yang and co-workers reported the use of the pendant amino groups of UiO-66-NH2 to 
covalently attach positively charged quaternary ammonium salts (Q) by amide formation, to 
serve as threads for pseudorotaxanes at the MOF surface, reporting conversion of 41% of 
the amino groups, although some coordination of the threads through a carboxylate group is 
also evident in the 1H NMR spectra of acid-digested samples. The authors used 
supramolecular chemistry to cap the positively charged surface moieties of UiO-66-NH-Q 
with the negatively charged decacarboxylato-pillar[5]arene (CP5), forming UiO-66-NH-Q-
CP5 capped, which possesses [2]pseudorotaxanes as stimuli-responsive elements for 
triggered drug release [93]. Distinguishing capping CP5 from CP5 that is adsorbed to the 
SBUs at the surface through its carboxylate units is, however, troublesome. 
 
It has been reported that both folic acid (FA) and 5-carboxyfluorescein (5-FAM) can be 
dually covalently coupled to UiO-66-NH2 using the amide coupling reagent N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide (EDC) in aqueous suspensions containing the 
drug 5-fluorouracil, forming drug-loaded UiO-66-NH2-FA-5-FAM [94]. Again, distinguishing 
the formation of a covalent linkage between the MOF and the free carboxylate-containing 
reagents from postsynthetic coordination is difficult, with IR spectroscopy used in this report; 
mass spectrometry would provide more compelling evidence of the covalent conjugation.  
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Table 2. Literature examples of Zirconium MOFs functionalised by postsynthetic covalent 
modifications. 
MOF Surface Coating 
Modification 
Protocol 
Drugs Name During Review 
Enhanced 
Properties 
Ref 
UiO-66-
NH2 
PNIPAM-NHS Amide coupling 
Resoruflin 
Caffeine 
Procainamide 
UiO-66-PNIPAM 
On-off 
temperature 
release 
[92] 
UiO-66-
NH2 
1. Quaternary 
ammonium salts 
2.Carboxylato-
pillar[5]arene (CP5) 
1. Amide coupling 
2. Supramolecular 
chemistry 
5-Fluorouracil  
(5-FU) 
UiO-66-NH-Q-CP5 
capped 
Multi-stimuli 
responsive 
drug release 
[93], 
[99] 
UiO-66-
NH2 
Folic acid (FA) 
5-Carboxyfluorescein 
(5-FAM) 
Amide coupling 5-FU 
UiO-66-NH2-FA-5-
FAM 
Targeted drug 
delivery 
[94] 
UiO-67 
Zr-fum 
Galactosylamine Amide coupling - 
UiO-67-GS 
Zr-fum-GS 
Dyes 
encapsulation; 
Imaging 
[95] 
UiO-66 PEG-NH2 Amide couping 
Mn-doped for 
microwave 
therapy 
Mn-doped  
UiO-66-PEG 
Anticancer 
targeting; 
ROS 
production 
[96] 
UiO-66-N3 1. DBCO-DNA 1. SPAAC - UiO-66-DNA 
Stability and 
dispersion 
[97] 
UiO-68-N3 
1. DBCO-DNA  
2. Complementary 
DNA sequences 
1. SPAAC 
2. DNA 
hybridisation 
Doxorubicin 
(DOX) 
Methylene blue 
Rhodamine 6G 
UiO-68-N3-DNA 
Stimuli 
responsive 
release; 
Anticancer 
targeting 
[98] 
UiO-66-L1 
 
Propargyl-PEG550; 
Propargyl-PEG2000; 
Propargyl-Poly-L-
Lactide 
Click modulation 
(CuAAC) 
DCA  
UiO-66-L1-PEG550 
UiO-66-L1-PEG2000 
UiO-66-L1-PolyLact 
Stability and 
dispersion; 
Therapeutic 
efficiency 
[73] 
UiO-66-L2 Azide-PNIPAM 
Click modulation 
(CuAAC) 
DCA  UiO-66-L2-PNIPAM 
Stability and 
dispersion; 
Therapeutic 
efficiency 
[73] 
 
Postsynthetic surface modification based on condensation between terminal carboxylates of 
the framework ligands and amine functionalities of the surface reagents has also been 
reported. For example, galactosylamine has been coupled to terminal carboxylates of the 
linkers at the surfaces of UiO-67 and Zr-fum also using EDC as a coupling agent (Figure 6b), 
albeit with some loss of crystallinity of the samples [95], and amine-terminated poly(ethylene 
glycol) has been coupled to Mn-doped UiO-66, prepared by addition of MnCl2 to a typical 
UiO-66 solvothermal synthesis, in a similar manner, to form Mn-doped UiO-66-PEG [96]. 
Again, these MOFs were characterised by IR spectroscopy after the functionalisation 
protocol, making covalent bond formation difficult to determine, although coordination of 
terminal primary amines is less likely than terminal carboxylates. 
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In 2014, Mirkin et al. synthesised a UiO-66 analogue containing an azide group on its linker, 
UiO-66-N3, and subsequently covalently attached dibenzylcyclooctyne (DBCO) 
functionalised DNA to the MOF through copper-free, strain-promoted azide-alkyne 
cycloaddition (SPAAC) (Figure 6c) [97]. Through radiolabelling, the authors confirmed that 
PSM occurs only on the outer surface, as expected due to size-selectivity. Recently, Willner 
and co-workers reported the synthesis of UiO-68-N3 by postsynthetic transformation of UiO-
68-NH2, and also utilised the azide functionality to attach DBCO-functionalised DNA 
sequences through SPAAC. Sequential addition of a single oligonucleotide strand on the 
MOF surface followed by hybridisation with complementary strands allows incorporation of a 
diverse range of surface functionality, including pH-responsive sequences, aptamers, and 
DNAzymes [98]. 
 
We have introduced the concept of chemical transformations of functionalised modulators 
incorporated into UiO-66 at defect sites. Azide and propargyl-functionalised modulators 
located at the surfaces of UiO-66 were postsynthetically attached to various functionalised 
oligomers and polymers through copper(I)-catalysed azide-alkyne cycloaddition (CuAAC, 
Figure 7) [73, 74]. The polymers included poly(ethylene glycol) (PEG) chains of different 
lengths, poly-L-lactide terminated with propargyl groups, and PNIPAM terminated with azide 
groups, thus forming the surface functionalised UiO-66-L1-PEG550, UiO-66-L1-PEG2000, 
UiO-66-L1-PolyLact and UiO-66-L2-PNIPAM. Attachment was proved to occur only on the 
outer surface, without pore blockage, while covalent bond formation was confirmed by ESI-
MS analysis of digested samples. Additionally, controls in which the nanoparticles were 
stirred with the polymers without the presence of the Cu(I) catalyst showed no polymer 
conjugation or adsorption, confirming the nature of the attachment to be covalent. 
 
 
 
Figure 7. Schematic of the “click modulation” process to selectively surface modify UiO-66 with 
poly(ethylene glycol) chains. Modified with permission from ref [73] copyright (2017) Elsevier. 
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3.4 Postsynthetic Noncovalent Modification 
 
Controlled supramolecular interactions can also be used to further surface modify MOFs 
(Table 3). Hong et al. reported the synthesis of a radiolabelled version of UiO-66 (89Zr-UiO-
66), which they functionalised with pyrene-derived PEG (Py-PGA-PEG) through π-π 
stacking interactions with the organic linkers of UiO-66 (Figure 8) [100]. The pyrene-derived 
PEG chains contained a terminal maleimide residue, which was used to further functionalise 
the MOF with a nucleolin-targeting peptide (F3) through postsynthetic addition to one of its 
cysteine residues. The authors found that the PEG units, due to their flexible structure, were 
partially blocking the porosity of the MOF, as a consequence of π-π stacking with organic 
linkers present inside the structure. They postulated that to control the distribution of PEG on 
the MOF’s surface, covalent attachment might be needed.  
 
 
 
Figure 8. Schematic self-assembly of radiolabelled UiO-66, followed by drug loading, noncovalent 
postsynthetic functionalisation, and peptide incorporation. Modified with permission from ref [100] 
copyright (2017) American Chemical Society. 
 
Other approaches, such as liposome encapsulation [101] or silica coating and subsequent 
surface functionalisation based on reactions with silica siloxane groups, have also been 
reported for other MOF systems [3, 102]. Although silica coating provides further stability 
under simulated physiological conditions, higher cytotoxic effects and a higher accumulation 
in the body are common drawbacks of this approach. To the best of our knowledge, this 
approach has not been used for the surface functionalisation of zirconium MOFs, possibly 
because their water stability is higher than for other MOF systems. Zr MOFs coated with 
poly(ξ-caprolactone) in the form of microparticles have recently been reported [103]. The 
authors investigated UiO-66 and UiO-67 microencapsulation with a copolymer of poly(ξ-
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caprolactone) and D-α-tocopherol polyethylene glycol 1000 succinate (PCL-TPGS), a 
derivate of vitamin E and PEG. Large quantities of drug-loaded MOFs were successfully 
incorporated into micron-scale polymer spheres.  
 
Table 3. Literature examples of Zirconium MOFs functionalised by noncovalent modifications or 
multiple protocols. 
MOF Surface Coating 
Surface 
Modification 
Protocol 
Drugs 
Name during the 
review 
Enhanced 
Properties 
Ref 
89
Zr UiO-
66 
1. Pyrene-derived PEG 
(py-PGA-PEG) with 
maleimide residue 
2. F3 Targeting peptide  
1. - interaction 
2. Maleimide-thiol 
coupling 
DOX 
89
Zr-UiO-66-Py-
PGA-PEG-F3 
pH-responsive 
drug release; 
Positron emission 
tomography (PET) 
[100] 
UiO-66 
UiO-67 
Modified poly(ξ-
caprolactone) (PCL-
TPGS) 
Microencapsulation 
Paclitaxel 
Cis-platin 
UiO-66 -PCL-TPGS 
UiO-67 -PCL-TPGS 
Prolonged drug 
release 
[103] 
PCN-224 
1. Nα,Nα-
bis(carboxymethyl)-l-
lysine 
2. DNA 
3. NaFY4:Yb/Er UCNPs 
1. PS coordination 
of carboxylates 
2. Amide coupling 
3. SPAAC 
4. DNA hybridisation 
- PCN-224-UCNP Targeted PDT [104] 
 
Finally, a combination of the coordination, covalent, and supramolecular approaches has 
been used to functionalise PCN-224. The amino acid Nα,Nα-bis(carboxymethyl)-l-lysine was 
attached to the surface by coordination of its three carboxylates, followed by covalent amide 
conjugation to a bifunctional linker with an activated N-hydroxysuccinimide (NHS) ester and 
a DBCO unit. Subsequent SPAAC allowed conjugation of azide-modified DNA, 
complementary strands of which were attached to lanthanide-based upconverting 
nanoparticles (UCNPs). Complementary base-pair recognition resulted in the formation of 
MOF-UCNP composites that were used for PDT [104]. There are clearly a number of 
protocols for modifying the outer surfaces of MOF nanoparticles, both during and after 
synthesis, and that are compatible with cargo loading. Each method has its own particular 
advantages, but a comprehensive comparison of the different protocols, with respect to 
efficacy, surface coverage, and stability, has not been carried out, and would greatly inform 
the disparate groups working in this area. 
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4. Colloidal Dispersion and Stability of Zirconium MOFs 
 
To ensure the safe and efficient use of MOFs in medicinal applications, they must be stable 
towards aggregation and hydrolysis in aqueous solvents. Good water dispersion is vital for in 
vivo treatment, as blood is an aqueous, phosphate-containing fluid, and aggregation could 
result in harmful capillarity blockage. As zirconium has a greater affinity for phosphates than 
for carboxylates, phosphates present in the body can also attack the zirconium positions, 
inducing degradation and thus resulting in uncontrollable release of the drug, negating the 
drug delivery effect [45]. It is, however, important to take into account that the ultimate 
aggregation that NMOFs will suffer in the blood current is difficult to predict. In vitro studies 
using phosphate buffered saline (PBS, which has a higher phosphate concentration than 
typically found in blood) or water as dispersants have been widely used in order to evaluate 
their behaviour in aqueous media, as well as the effect of the presence of phosphates on 
their colloidal stability. Other dispersants, such as growth media, serum, or PBS spiked with 
diverse proteins, have been exploited to study the presence of blood containing proteins in 
the dispersion of NMOFs [41].  
 
Fairen-Jimenez et al. have recently studied the colloidal stability of the UiO-66 family of Zr 
MOFs using dynamic light scattering (DLS) in PBS and growth media. It was found that all 
the MOFs  aggregate significantly in PBS, whereas no major aggregation was found when 
the MOFs were dispersed in growth media, possibly as a consequence of the formation of a 
protein corona on the surface of the NMOFs [105]. This phenomenon has also been 
observed for other MOF systems [41, 106]. Rapid degradation of benzoic acid modulated 
UiO-66 in PBS at pH 7.4 was observed by UV/visible spectroscopy, releasing 80% of the 
terephthalic acid linker during the first hour, but not in water, where less than 10% of the 
linker was released after 7 days. The samples were characterised after different exposure 
times in PBS, confirming the formation of a phosphate corona by FT-IR spectroscopy, as a 
consequence of phosphate attacking the Zr units and displacing the linkers. Similar high 
degradation rates in PBS were found for other members of the UiO-66 isoreticular series, 
which could result in unwanted uncontrollable release of drugs. We have observed slightly 
slower degradation kinetics for AcOH modulated UiO-66, which took 8 h of immersion in 
PBS to release 80% of the bdc linker, suggesting modulators may play some role in stability 
to phosphate-induced degradation [73]. 
 
Surface modifications are known to play a crucial role in the hydrolytic stability and colloidal 
dispersion of MOFs and DDSs in general, as they govern the interactions with the media in 
which DDSs are dispersed and can shelter the Zr6 SBUs from attack by nucleophilic ions 
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such as phosphate. For example, UiO-66-N3 nanoparticles in water aggregate quickly upon 
NaCl addition, however, UiO-66-N3-DNA conjugated nanoparticles are colloidally stable in 
aqueous solutions of up to 0.4 M NaCl, possibly due to the steric and electrostatic barriers 
provided by the DNA surface coating [97]. Surface modification with the phospholipid L-
DOPA can even enable the dispersion of hydrophilic Zr MOFs in low polarity media such as 
CHCl3. Thus, UiO-66-DOPA, UiO-67-DOPA and BUT-30-DOPA migrated from the aqueous 
to the organic phase upon liquid-liquid extraction (Figure 9) [88]. 
 
 
 
Figure 9. Images of a) bare Zr MOF nanoparticles suspended in water, and b) DOPA-coated Zr MOF 
transferred to CHCl3. c) SEM image of UiO-66-DOPA dropcast from CHCl3. Scale bar 1 m. Modified 
with permission from ref [88] copyright (2015) John Wiley and Sons. 
 
The effect of incorporating phospholipid mono- and bilayers into MOFs was investigated 
through examining the colloidal stability and dispersion of bare PCN-223 nanoparticles, 
nanoPCN-223@DOPC and nanoPCN-223@DOPC/DOPC in a series of solvents, such as 
water, PBS and biological growth media [90]. The hydrodynamic size of bare nanoPCN-223 
drastically increased with time in water and more importantly in PBS, indicating significant 
aggregation. As a consequence of phosphate attack, 90% of the linker was released from 
bare nanoPCN-223 in the first hour of PBS exposure. Upon the first coating with the 
phospholipid DOPC, PCN-223@DOPC was found to be highly hydrophobic and aggregated 
in water, likely due to the acyl chains of DOPC. In contrast, the MOFs coated with 
phospholipid bilayers did not significantly aggregate in water or PBS over a period of 7 days, 
highlighting the power of surface modifications. Both mono- and bi-layer coated 
nanoparticles were stable towards common cations and anions, as well as in serum. PCN-
223 coated with PBLs releases less than 3% of the organic linker after 7 days in PBS, 
strongly suggesting that PBLs act as a barrier to block phosphate attack, with PBL coatings 
even providing additional resistance towards H2O2. The combination of polymer-coating and 
the high coverage provided by the postsynthetic coordination protocol ensures excellent 
stability. 
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We have investigated the aggregative behaviour of a range of polymer-coated UiO-66 
derivatives, finding that after covalent surface PEGylation, UiO-66-L1-PEG550 and UiO-66-
L1-PEG2000 were well dispersed in PBS, with average hydrodynamic diameters close to the 
ones measured by SEM [73]. Enhancements in the stabilities of the PEGylated MOFs in 
PBS were also achieved. An induction time was found, during which PEGylated samples did 
not undergo notable linker release; only 35% of BDC was released after 3 h, and crystallinity 
was not affected. Importantly, after 24 h of exposure nearly all the linker had been released, 
indicating that although an initial stability enhancement is found – possibly as a 
consequence of the PEG coating initially hindering phosphate attack – full degradation will 
occur (Figure 10), which is vital for clearance in vivo. Significant enhancements in 
polydispersity and stability were also found when UiO-66 was functionalised with poly-L-
lactide and PNIPAM through the same methodology, although coordination of heparin to the 
surface through its sulfate units did not notably improve dispersion [74]. 
 
 
 
Figure 10. a) Degradation profiles monitoring linker release by UV/Visible spectroscopy and b) 
powder X-ray diffraction analysis showing an enhancement in the stability of UiO-66 in PBS when 
coated with poly(ethylene glycol) chains. Used with permission from ref [73] copyright (2017) Elsevier. 
 
We have also investigated the stability of UiO-66 samples functionalised by introducing folic 
acid or biotin as modulators in one-pot syntheses, and compared them to the analogous 
samples functionalised by postsynthetic coordination, allowing comparison of stability 
enhancements endowed by differing functionalisation protocols. The samples prepared by 
postsynthetic coordination had a greater induction time in which degradation was slower 
than the samples synthesised by one-pot coordination modulation, possibly due to more 
complete coordination of surface Zr units. However, after the induction period, the samples 
synthesised by coordination modulation had lower degradation rates, and all biotin and folic 
acid functionalised samples were more stable towards PBS than bare UiO-66. 
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Hong and co-workers found slight changes in aggregative behaviour when UiO-66 was 
dispersed in water before and after supramolecular Py-PGA-PEG functionalisation. The 
hydrodynamic diameter of bare UiO-66 (~220 nm) was slightly higher than the size observed 
by SEM, and increased further for UiO-66-Py-PGA-PEG-F3 (~250 nm) [100]. These results 
suggest that, although many factors are involved in controlling the aggregative behaviour of 
MOFs, surface functionalisation through covalent attachment might be more efficient at 
enhancing colloidal stability of UiO-66 than using π-π interactions, possibly due to the higher 
stability of the coating using the former protocol. 
 
Mirkin and co-workers have recently reported that the monocarboxylic acid modulator used 
during UiO-66 synthesis plays a crucial role in the MOFs polydispersity [107]. Modulators 
with lower pKa values are more likely to be deprotonated during synthesis, and so increased 
competition with the organic linker for the zirconium positions induces the formation of 
defects (see for example, Figure 3b). These defects increase the surface charge (measured 
by zeta potential), thus increasing the repulsion between nanoparticles and enhancing their 
colloidal stability. UiO-66 samples modulated by formic acid (pKa = 3.8), dichloroacetic acid 
(pKa = 1.4) and trifluoroacetic acid (pKa = 1.1) were colloidally stable in water, as determined 
by DLS, and did not show any aggregation by scanning tunnelling electron microscopy 
(STEM). In contrast, when acetic acid (pKa = 4.8) is used as a modulator for the synthesis of 
UiO-66 (the BDC linker has a first pKa of 3.5 and a second of 4.8) the resultant particles 
were considerably aggregated. 
 
In the course of our own research, we independently realised that DCA, a molecule with 
anticancer activity, could be deliberately incorporated into UiO-66 in significant amounts 
(20% w/w) during synthesis, as a consequence of its lower pKa value [73]. This protocol was 
further explored introducing functionalised modulators (azide, or propargyl benzoic acid 
derivatives) or biomolecules (folic acid, biotin) together with DCA as the co-modulator, 
yielding DCA@UiO-66-modulator (CM) in one simple synthetic step. In correlation with the 
observations by Mirkin, the hydrodynamic diameters of the various MOFs in PBS and water 
were close to those determined by SEM, again showing little aggregation when DCA is used 
as co-modulator, in contrast to AcOH modulated UiO-66 [74]. 
 
The biodegradation of Mn-doped UiO-66-PEG has been investigated in artificial lysosomal 
fluid (pH 4.5) to mimic intracellular conditions upon different soaking times (1, 9, 12 and 24 
h) [96]. Although after 9 h the morphology of the MOF is significantly altered, as confirmed 
by TEM imaging, some Bragg reflection peaks can still be observed by PXRD analysis of 
dried samples, which completely disappear after 24 h, suggesting that the MOF can degrade 
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in vivo after performing its task. The authors observed that after one hour the MOFs start to 
aggregate, with complete agglomeration after 9 h. 
 
The stability of MOFs towards phosphates depends on many factors, but clearly surface 
coating is one of the most important, as it can shelter metal clusters from phosphate attack. 
Compared to the amount of work that has been performed to determine and to enhance the 
drug release kinetics of Zr MOFs, there are few studies in the literature that discuss the 
degradation kinetics of the Zr MOF itself, despite the fact that the drug release will, in part, 
be a consequence of carrier degradation. It is evident that both hydrolytic stability and 
colloidal dispersion are closely related; notable improvements in both are possible through 
surface functionalisation based on phosphate coordination and covalent postsynthetic 
modification. The use of a low pKa modulator during the synthesis of UiO series MOFs 
significantly enhances their colloidal dispersion; it may be expected that this will also 
enhance hydrolytic stability by increasing the strengths of the bonds between the Zr SBUs 
and the carboxylates of the linkers [108]. 
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5. Controlling Cargo Release 
 
For DDSs to be effective, premature release of therapeutic cargo should be minimised, 
allowing the drug to travel to the location of the disease within the body before delivering the 
payload. For MOFs, release of cargo can occur by diffusion out of the pores or through 
degradation of the MOF itself, with unwanted early release – the so-called “burst release” 
phenomenon – a major issue to overcome. The chemical stability and ease of 
functionalisation of Zr MOFs has facilitated the development of many strategies to allow 
controlled or even stimuli-responsive cargo release. As hydrolytic stability is implicit in 
control of cargo release, similar protocols to those discussed in Section 4 have been 
employed to overcome burst release in Zr MOFs.  
 
Attaching cargo to the surfaces and defect sites of Zr MOFs by coordination provides the 
possibility of pH or phosphate induced cleavage and release. For example, Lachelt and co-
workers studied the release of fluorescent peptides, attached to Zr-fum surfaces using His-
tag imidazole coordination, into HEPES buffered glucose (HBG) at different pH values over 
24 h by photometric determination (Figure 11) [85]. HBG does not contain phosphates, so 
the role of pH can be assessed independently. At pH 7.4 the coating was stable, while at pH 
5 the peptide was partially released, and at pH 3 was completely cleaved from the surface of 
Zr-fum. Although the imidazoles present in histidine residues have pKa values around 6, and 
thus detachment at pH 5 due to imidazole protonation would be expected to be more 
pronounced, the authors suggest that incomplete detachment could be due to the lowered 
effective pKa value when His-tags are attached to the zirconium units. 
 
 
 
Figure 11. a) Schematic release of his-tagged peptides from Zr-fum by decreasing pH. b) 
Assessment of pH induced released peptides by absorbance at  = 646 nm, with photographic 
images showing decrease in colour as peptide is release. Modified with permission from ref [85] 
copyright (2017) American Chemical Society. 
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The coordination of the drug Alendronate through its phosphate groups to UiO-66 results in 
pH responsive drug release from UiO-66-AL, which released 43% of AL in PBS at pH 7.4 
over 60 h, and 59% of AL under the same conditions but at pH 5.5 [84]. In this case, the 
release at pH 7.4 is likely a consequence of phosphate substitution, which is somewhat 
enhanced at pH 5.5. Since the pKa of alendronate is lower than free phosphate, the less 
pronounced release rates at pH 5.5 might be a consequence of the equilibrium between 
protonated and non-protonated alendronate and phosphates.   
 
If molecular cargo is tightly bound by the host MOF then temperature can be used to induce 
its release. Jiang et al. compared the release of the drug diclofenac sodium (DS) from the 
UiO series MOF NU-801 (3,3ʹ-(1,4-phenylene)diacrylic acid linker) with a derivative 
containing a central 1,4-naphthyl spacer, ZJU-801.[109] Release of the drug from DS@NU-
801 into PBS was characterised by a burst release, with only a slight enhancement as 
temperature was increased from 25 °C to 60 °C, and ~80% release at 37 °C in 24 h. In 
contrast, DS@ZJU-801 releases only ~25% of its cargo at 37 °C in 24 h, but is completely 
evacuated over the same time period at 60 °C. The difference in release is ascribed to 
enhanced π-π stacking between ZJU-801 and DS. 
 
Physically modifying drug-loaded MOFs to sterically protect the surface from hydrolysis is 
also an effective approach to control drug release (Table 4). Fairen-Jimenez et al. have 
applied an amorphisation approach to trap calcein, a model drug molecule, within UiO-66 by 
grinding. Full release of calcein from amorphous UiO-66 took 30 days rather than two days 
for crystalline UiO-66 (Figure 12a) [110], and 15 days instead of two for amorphous UiO-66-
NH2 [105]. Similarly, the release of (DS) from ZJU-800, a member of the UiO series linked 
by 3,3ʹ-(2-fluoro-1,4-phenylene)diacrylic acid, was monitored in PBS by Jiang et al [111]. DS 
was loaded into ZFU-800 up to 59% w/w, and its release in PBS (pH 7.4) at 37 °C displayed 
a burst effect, with an immediate 10% release, followed by full release over two days. The 
effect of pressure on the drug release kinetics was investigated by applying different 
pressures (10 MPa and 30 MPa) to drug loaded samples for one minute, compacting the 
MOFs into slices, which were further broken for the drug release experiments. The authors 
observed a 2.5 fold decrease in the release rates for the lower pressure, maintaining the 
release up to 5 days, and when the higher pressure was applied, the release was prolonged 
to 8 days, with no burst release for either sample (Figure 12b). Whilst bulk crystallinity was 
maintained, pressure-induced amorphisation at particle surfaces could sufficiently block 
pores and slow down release. 
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Table 4. Postsynthetic treatment of Zr MOFs to enhance drug release kinetics.
[a]
  
MOF 
Drug/ 
Biomolecule 
Treatment Applications Ref 
UiO-66 Calcein 
Mechanical 
amorphisation 
Prolonged release from 2 to 30 
days in PBS 
[110] 
UiO-66-X 
DUT-52 
UiO-67 
Calcein 
-CHC 
Mechanical 
amorphisation 
Prolonged release in PBS; 
Enhanced cytotoxicity 
[105] 
ZJU-800 
Diclofenac 
disodium (DS) 
Pressure 
application 
Pressure-controlled release [111] 
NU-1000 
NU-901 
Calcein 
-CHC 
Temperature 
treatment 
Prolonged release in PBS; 
Enhanced cytotoxicity 
[112] 
[a]
Some examples of incorporation of stimuli-responsive release mechanisms on the surfaces of Zr 
MOFs are given in Table 2. 
 
Thermal amorphisation has been also investigated to prolong the drug release times of NU-
1000 and NU-901 [112]. These zirconium MOFs have remarkably high storage capacities – 
with calcein loadings of 41.6% w/w and 37.0% w/w, respectively – due to their high porosity 
(SBET = 2320 and 2500 m
2g-1, respectively), but their larger pore cavities can at the same 
time result in rapid drug release. Calcein was confirmed to be located in the pores, as the 
loaded samples had drastically reduced porosities. Temperature treatment (180 °C) was 
performed in order to collapse the structure and to hinder calcein release through the pore 
cavity. In contrast to the mechanical amorphisation protocols performed on the UiO-66 family 
[105, 110], although the intensity of the Bragg peaks had decreased, they could still be 
observed clearly in the PXRD pattern, indicating only partial structure collapse.  
 
 
 
Figure 12. Release profiles of a) calcein from pristine (filled symbols) and amorphised (empty 
symbols) UiO-66, b) diclofenac sodium from ZJU-800 treated at different pressures, and c) calcein 
from pristine (filled symbols) and temperature amorphised (empty symbols) NU-1000. Modified with 
permission from a) ref [110] copyright (2015) The Royal Society of Chemistry, b) ref [111] copyright 
(2016) Royal Society of Chemistry, and c) ref [112] copyright (2017) American Chemical Society. 
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The effect of thermal treatment on the drug release kinetics was clear; after 4 h cal@NU-
1000 had released ~28% of its calcein, but after thermal treatment only 10% was released in 
the same time period. The release kinetics were slowed to the seventh day, when the 
profiles for thermally amorphised and pristine calcein-loaded NU-1000 overlap at around 
80% release, and continue to release the full amount up to seven weeks (Figure 12c). On 
the other hand, only a minor effect on calcein release kinetics was found upon thermal 
treatment of NU-901. 
 
Encapsulation of MOF nanoparticles in polymer microspheres can also control release. UiO-
66 and UiO-67 were loaded with cisplatin (4.8% w/w and 1% w/w, respectively) and taxol 
(14% w/w and 10% w/w, respectively) before microencapsulation in modified poly(ξ-
caprolactone), and their release kinetics in PBS (pH 7.4) were investigated [103]. Burst 
release of cisplatin from uncoated UiO-66 and UiO-67 was observed (70% and 90% release, 
respectively, after 5 h of exposure) followed by slow release of the remainder, either as a 
consequence of the majority of the drug being bound to the surfaces of the MOFs rather 
than stored in their pores, or to carrier instability. Similar burst release (50-60%) of taxol was 
observed from the bare MOFs. The burst effect was considerably reduced after 
microencapsulation of the nanoparticles for both drugs, with a more pronounced effect for 
cisplatin, which showed sustained release for 18 days. 
 
In Section 4, a number of examples were detailed where incorporation of surface 
functionality blocked phosphate-induced degradation; surface units can also block the 
release of cargo molecules until certain external stimuli are applied. We have shown that 
calcein release from UiO-66 can be controlled by postsynthetic covalent PEGylation through 
click chemistry at functionalised modulators [73]. Release profiles into PBS, measured by 
UV/Vis spectroscopy, showed that unfunctionalised cal@UiO-66-L1 released all its calcein in 
2 days at pH 7.4, but cal@UiO-66-L1-PEG2000 only released ~30% of loaded calcein under 
the same conditions. We hypothesise that when UiO-66 is coated by PEG chains, once the 
phosphates diffuse through the protecting coating and begin to displace the polymer and 
calcein attached to the surface, a phosphate corona that hinders further calcein release is 
formed. Bare and coated samples release ~90% of the loaded calcein in PBS at pH 5.5 after 
only ten hours, with the lower pH conditions allowing displacement of surface phosphates 
and the remainder of the calcein. This behaviour allows pH-responsive release of calcein 
from cal@UiO-66-L1-PEG2000 upon addition of acid (Figure 13); the lower pH of some 
cancer cells could allow this to be a mechanism for controlled delivery and release of 
anticancer therapeutics.  
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Figure 13. pH responsive release of calcein from PEGylated UiO-66 samples. Modified with 
permission from ref [73] copyright (2017) Elsevier.  
 
PNIPAM is thermosensitive polymer, which is adopts a closed, globular mode at higher 
temperatures, and opens to a coil formation at lower temperatures. Thus, Kokado and Sada 
reported the on-off thermoresponsive release of three different molecules – resorufin, 
caffeine and procainamide – from UiO-66-PNIPAM in water [92]. The release kinetics at 25 
°C were slightly improved compared to the precursor UiO-66-NH2, to which PNIPAM was 
attached by amide formation, which released ~95% of resorufin after a few hours. Drug 
release from the PNIPAM-functionalised MOF was pronounced at 25 °C, when the polymer 
is in its open coil form, exhibiting a burst release of more than 50% of the different molecules 
in the first few hours and 80-90% release after one day. The release kinetics were 
remarkably reduced at 40 °C, with an initial release of only 10-20% of the cargo molecules in 
the first hour, with no subsequent release. As the drugs were loaded after PSM, the small 
amount of drug released initially at 40 °C could be a consequence of minor surface drug 
location. By changing the temperature during the course of the drug release experiment, 
UiO-66-PNIPAM drug release was switched on and off by external stimulus (Figure 14a). It 
is important to point out that this temperature responsive behaviour was only achieved when 
the degree of PNIPAM coating was high enough to ensure significant surface coverage, as a 
sample with only 4.2% w/w PNIPAM did not present thermoresponsive behaviour.  
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Figure 14. a) Schematic showing temperature induced release of cargo from UiO-66-PNIPAM. 
Modified with permission from ref [92] copyright (2015) The Royal Society of Chemistry. b) Schematic 
showing Mg
2+
 and adenosine triphosphate (ATP) induced release of cargo from UiO-68 functionalised 
with metal-sensitive DNAzymes. Modified with permission from ref [98] copyright (2017) The Royal 
Society of Chemistry. 
 
Willner et al. studied the reorganisation of DNA on the surface of UiO-68-N3 in response to 
pH and metal ions as mechanisms for the release of doxorubicin (DOX) and methylene blue 
[98]. To induce pH responsive release, cytosine-rich DNA sequences were attached to the 
surface of UiO-68-N3 by SPAAC, and the authors attributed the enhanced release of cargo 
into PBS at pH 5 compared to that at pH 7.4 to the reorganisation of the cytosine-rich DNA 
into an i-motif structure that allowed cargo to be released, rather than linker deprotonation 
and structure decomposition. Metal ion responsive release was probed by attaching metal-
ion-dependent catalytic nuclei acid sequences – so-called “DNAzymes” – through 
hybridisation with pre-installed surface sequences. Upon metal-ion binding, these 
DNAzymes are released from the MOF and should result in uncapping and release of 
trapped cargo, in this case the dyes rhodamine 6G and methylene blue, as well as 
doxorubicin. 
 
The release of rhodamine 6G (Mg2+) and methylene blue (Pb2+) from UiO-68-N3-DNA was 
induced by the presence of the metal ions in a concentration and time dependent manner. 
The doxorubicin-loaded MOF was functionalised with DNA containing both an Mg2+ 
dependent DNAzyme sequence and an adenosine triphosphate (ATP) aptamer unit, based 
on the fact that ATP concentrations are higher in cancerous cells than healthy ones (Figure 
14b). Release was only slightly enhanced upon increase of Mg2+, but a two-fold increase 
was promoted through cooperation of Mg2+ and ATP addition. It should be noted that the 
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phosphate units of ATP may also become involved with coordination to the Zr6 SBUs at the 
surface of the MOF. 
 
Yang and co-workers studied the stimuli-responsive release of 5-fluorouracil (5-FU) from 
pseudorotaxane capped 5-FU@UiO-66-NH-Q-Cp5 capped in aqueous solution in response 
to changes in pH, temperature, and the presence of various concentrations of Ca2+ [99] and 
Zn2+ ions [93], which have high affinity for decacarboxylato-pillar[5]arene (CP5), the 
macrocyclic component of the capping pseudorotaxanes. The capped MOF released around 
10% of 5-FU at pH 7.4 (25-37 °C) after one hour, and lower pH values resulted in an 
increase of the drug release rate, with 60% of drug released at pH 2 over the same time 
frame, likely due to hydrolytic cleavage of the surface functionality. Increased temperature 
also resulted in a more pronounce release rate. Because of the favourable binding between 
Ca2+ and the carboxylate-functionalised CP5 macrocycle, 5-FU release from 5-FU@UiO-66-
NH-Q-Cp5 capped was triggered in a stimuli-responsive manner by increasing Ca2+ 
concentration [99], releasing the full amount of the drug for Ca2+ concentrations of 600 mM in 
two hours. Significantly lower Zn2+ concentrations (10 nM) were sufficient to achieve 75% 
release in one hour [93]. Control experiments without CP5 capping resulted in total drug 
release after 2 days, indicating that the CP5 molecule hinders cargo release, although it is 
difficult to distinguish if the molecule acts as the wheel of a pseudorotaxane or simply a 
surface-adsorbed cap, or indeed both.  
 
We can observe that in general all zirconium MOFs have pH-responsive drug release as a 
consequence of hydrolysis, which is favourable for anticancer treatment, as the cytoplasm of 
cancer cells is generally more acidic than for healthy cells [113]. If we compare the release 
kinetics of different drugs from UiO-66, it comes to mind that cargo attached to the Zr 
clusters (such as Alendronate) are released with a more favourable rate than molecules 
stored in the pores (such as caffeine or resorufin). The importance of surface coating is 
obvious and has different effects depending on its nature. For example, surface coatings 
which can compete with phosphates during degradation highly enhance the stability of the 
samples through coordinative competition, and protecting polymers attached to the surfaces 
of NMOFs also sterically protect them from degradation, although to a lower extent, as once 
the coating has been displaced, degradation occurs at a normal rate. Protocols to collapse 
the porosity of MOFs around loaded molecules – such as mechanical amorphisation, 
temperature treatment, or applied pressure – have also induced more desirable release 
fates, although their effect on colloidal stability is not pronounced, indicating that surface 
coatings are more suitable to enhance both stability and dispersion. Thus, an appropriate 
strategy could be to perform surface coating after amorphisation.   
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6. In Vitro Studies of Zirconium MOFs 
 
To be efficient DDSs, MOFs should be easily internalised by the cells that they are aiming to 
treat, and able to release their cargo in intracellular conditions. Importantly, the DDS should 
avoid immune system recognition, and thus not be internalised by immune system cells such 
as macrophages. Nanoparticle uptake depends on many factors, including size, morphology 
and surface chemistry among others [114-116], and attempts have been made to enhance 
uptake and also control the endocytosis mechanisms of MOFs. Fluorescent linkers, surface 
functionality, or cargo molecules are usually used to monitor endocytosis of MOFs through 
confocal microscopy and/or fluorescence-activated cell sorting (FACS). It is also possible to 
quantify MOF content in cells through elemental analysis of Zr. 
 
 
6.1. Enhancing and Targeting Cellular Uptake of MOFs 
 
A number of protocols have been investigated to enhance the uptake of MOFs, and/or their 
cargo, by different cell lines, as well as induce particular intracellular localisation, and to 
target certain diseases. Different groups have found that uptake of MOF nanoparticles by 
cells occurs rapidly. Xie and co-workers investigated internalisation of UiO-PDT by B16F10 
mouse melanoma cells for different incubation times (0.5, 2 and 4 h) using FACS, and 
compared it with the mean fluorescence intensity when cells were incubated with the same 
concentration of free linker (I2-BDP), which exhibits characteristic fluorescence [86]. A dose-
responsive behaviour for the uptake of both was found, being higher (1.5 fold increase at 2 h 
incubation time) in the case of UiO-PDT. By confocal fluorescence microscopy it was 
observed that the red fluorescence was mainly located in the cytoplasm of B16F10 cells for 
both cases. Internalisation of UiO-66-FMN by HepG2 human liver carcinoma cells has been 
investigated after 4 and 12 h incubation time, finding that after 4 h more than 80% of the cell 
population have high mean fluorescent intensity, while after 12 h only a slightly increase is 
found [84]. These results indicate that UiO-66-FMN cell uptake occurs rapidly during the first 
4 h, after which the cell uptake rate decreases. Through confocal microscopy, high green 
fluorescence in the cells cytoplasm was observed. 
 
Zhou and co-workers investigated HeLa human cervical cancer cells uptake of a porphyrinic 
MOF (PCN-224) by varying particle size, with the aim to enhance internalisation and 
cytotoxicity through passive targeting [83], based on the fact that nanoparticles accumulate 
in cancer tissue due to the enhanced permeability and retention (EPR) effect [117]. The 
authors analysed the zirconium content by ICP-MS of digested cells, which were incubated 
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with samples of the MOF of varying size (30, 60, 90, 140, and 190 nm) over different times 
(0-40 h). The highest cell uptake was found for nanoparticles of 90 nm diameter, and 
generally reached a plateau after 12 h of incubation. Confocal microscopy showed the 
NMOF was located in both the lysosomes and mitochondria, while no nucleus co-localisation 
was found.  
 
Incubation of HeLa cells with porphyrin-coated UiO-66-TPP-SH and TCPP@UiO-66 (15 
µgmL-1) for only 2 h resulted in fluorescence located in the cytoplasm, suggesting that both 
MOFs have good membrane permeability. However, red fluorescence was also observed in 
the cytoplasm after incubation with free TPP-SH, suggesting passive diffusion of the free 
porphyrin, which would also occur if the surface ligands detach from the MOFs prior to 
endocytosis [80]. Similarly, after just one hour of incubation of HepG2 cells with the 
porphyrin-containing Zn-DTPP-I2@UiO-66 (10 µgmL-1), confocal microscopy showed 
fluorescence associated with the porphyrin to be located in the cytoplasm [79].  
 
Surface modification has been used to enhance endocytosis efficiency and tune the cell 
uptake routes of MOFs. We have found that functionalisation of UiO-66 with polar pendant 
moieties (Br, NO2, NH2) enhances uptake by HeLa cells compared to less polar derivatives 
such as DUT-52 and UiO-67 [118]. Mirkin et al. incubated UiO-66-DNA with HeLa cells for 
24 h, with fluorescent Tamra functionality on the DNA showing that conjugation to the MOF 
results in enhanced uptake of the DNA sequence. ICP-MS analysis of the zirconium content 
of the cells showed enhanced uptake for the UiO-66-DNA conjugates compared to bare 
MOFs, which was more remarkable for 19 nm sized nanoparticles than for 14 nm 
nanoparticles [97]. 
 
The intracellular bio-stability of PCN-223 has been investigated by quantification of linker 
release inside cells [90]. The authors incubated HeLa and human hepatocarcinoma SMMC-
7721 cells with bare nanoPCN-223, PCN-223@DOPC/DOPC and TCPP, the linker of the 
NMOF, which is itself fluorescent and thus allows tracking of MOFs inside the cells (Figure 
15). Passive uptake of free TCPP leads to low, well-distributed red fluorescence confined to 
the cytoplasm, while when cells were incubated with solutions of the bare MOF, only traces 
of nanoPCN-233 were observed as well-defined dots in the lysosomal locations inside the 
cells. Free TCPP located uniformly in the cell could also be observed, indicating possible 
degradation of the MOF sample in growth media, presumably due to the presence of 
phosphates in the media. In contrast, they found that PBL-coated nanoPCN-223 is only 
located in the lysosomes with no evidence of released TCPP in the cytoplasm. FACS 
showed that although TCPP undergoes passive diffusion into the cell and the mean 
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fluorescence intensity is similar to bare nanoPCN-223, after coating with PBLs the cell 
uptake efficiently is enhanced ~1.7 fold within the first 4 h of incubation, as no increase in 
fluorescence was found after longer incubation times of 12 and 24 h. 
 
 
 
Figure 15. a) Confocal fluorescence microscopy of SMMC-7721 cells after incubation with TCPP (free 
ligand), bare PCN-223, and PCN-223@DOPC/DOPC. Bio-TEM images of b) and c) bare PCN-223 
compared to d) and e) PCN-223@DOPC/DOPC, showing enhanced intracellular stability of PCN-
223@DOPC/DOPC. Reproduced with permission from ref [90] copyright (2017) American Chemical 
Society. 
 
We have analysed the internalisation of bare and surface functionalised UiO-66, loaded with 
fluorescent calcein, by J774 mouse macrophages, finding that in general, surface 
functionalised MOFs are internalised by macrophages to a higher extent than analogous 
bare MOFs, with a similar trend to HeLa cell internalisation efficiency [74]. Only PEG coating 
decreases macrophage uptake compare to the bare MOF, indicating that this coating might 
be desirable for selective anticancer treatment, as it decreases recognition by immune 
system cells. Internalisation of biotin-coated UiO-66 by HeLa cells was remarkably reduced 
compared to the naked NMOF. In fact, cal@UiO-66-Biot cell uptake did not significantly 
decrease at 4 °C compared to when cells were treated with the functionalised MOF at 37 °C, 
indicating that there is no efficient active transport.  
 
Targeting peptides have also been utilised to enhance MOF uptake by particular cell lines. 
DOX@UiO-66-Py-PGA-PEG-F3 (where the fluorescence of doxorubicin serves to track the 
location of NMOFs inside the cell) internalisation by human breast adenocarcinoma MDA-
MB-231 cells was found to be remarkably higher than DOX@UiO-66-Py-PGA-PEG, as 
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determined by flow cytometry measurements and confocal microscopy. This is because 
MDA-MB-231 cells over express the nucleolin receptor (n+), which is targeted by the F3 
peptide attached to the MOF [100]. In contrast, both targeted and non-targeted NMOFs were 
internalised considerably less by L929 mouse fibroblast cells, which do not over express the 
nucleolin receptor (n-). DOX fluorescence was mainly located in the cytoplasm, with some 
co-localisation in the lysosome when fluorescein isothiocyanate (FITC) modified MOFs were 
examined. The authors observed that for DOX@UiO-66-Py-PGA-PEG-F3, an internalisation 
plateau occurs within the first 0.25 h of incubation, in which a similar amount of internalised 
MOF and MOF binding to the cells surface was found. It was found that once internalised, 
during the next 24 h 30% of the NMOF can be externalised by cells through exocytosis 
processes.  
 
Targeting galactose-specific liver receptors resulted in an increased internalisation of Zr-fum 
(loaded with resorufin) and UiO-67 (loaded with Rhodamine 6G) by HepG2 liver cancer cells 
after galactosylamine coating, while cells incubated with uncoated analogue samples did not 
show appreciable uptake of the MOFs. Importantly, the targeting effect was evidenced by 
the fact that internalisation of the coated MOFs by HepG2 cells (which over express the 
receptor) is higher than by healthy FL83B mouse liver cells [95]. Folate targeting has also 
been used to enhance uptake of MOFs by cancer cells, and will be discussed in the context 
of receptor-mediated endocytosis in Section 6.2. 
 
Investigation of the fate of DDSs after cell internalisation can also provide key information to 
explain biological activity. For example, endosomal escape is a key feature for efficient 
siRNA delivery. Lin and co-workers performed co-localisation studies with human ovarian 
cancer SKOV-3 cells using confocal laser assisted microscopy, demonstrating siRNA and 
lysosome separation after 2 h incubation time [87]. The authors postulate that when 
siRNA@UiO becomes entrapped in the endosomes, the presence of high endogenous 
phosphate concentration and the acidic pH of those will result in structure degradation, and 
zirconium ions will disrupt the endosome structure, thus facilitating siRNA release.  
 
 
6.2. Endocytosis Mechanisms  
 
Nanoparticles are generally internalised by cells through active transport such as 
endocytosis, including clathrin-mediated, caveolae-mediated, and non-mediated 
endocytosis, and macropinocytosis, among others (Figure 16) [114, 119-122]. While 
nanoparticles internalised through clathrin-mediated endocytosis are finally delivered to 
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lysosomes, which can result in degradation and inefficient cytosolic release of their cargo, 
nanoparticles internalised through caveolae-mediated endocytosis can escape lysosome 
capture, typically resulting in faster cytosolic release, reaching the desired cell organelles in 
a more efficient manner and hence displaying higher therapeutic efficiency [123]. 
Macropinocytosis, whilst unselective, can result in uptake of large quantities of foreign 
material, some of which may also escape lysosomal degradation and excretion. 
 
 
 
Figure 16. Common endocytosis pathways observed for nanomaterials. Reproduced with permission 
from ref [122] copyright (2009) Springer Nature. 
 
The use of inhibitors of particular cell uptake pathways can allow internalisation pathways of 
MOFs to be studied by FACS. In 2016, Fairen-Jimenez et al. first reported the study of 
internalisation of calcein-loaded UiO-66 by HeLa cells, using inhibitors to suppress specific 
endocytosis routes [124]. Uptake of cal@UiO-66 was drastically decreased when cells were 
incubated with the MOFs at 4 °C rather than 37 °C, confirming that cell internalisation occurs 
predominantly by active transport. The authors observed that UiO-66 generally undergoes 
cell internalisation through clathrin-mediated endocytosis, with minor contributions of the 
macropinocytosis process. Only a minor contribution of the caveolae route was found when 
the size of the particles was increased from 150 nm to 260 nm. The clathrin-mediated route 
forms an early endosome, which is later transformed into a lysosome [125-127], while 
nanoparticles internalised through caveolae-mediated route are able to escape the early 
endosome, by the alternative formation of a caveosome that will release its content to the 
cytosol in a more efficient way [123, 128]. Macropinocytosis is a process in which cells 
uptake large quantities of fluids [129]. Thus, the therapeutic efficiency of nanoparticles 
internalised by clathrin-mediated route is expected to be generally lower than for those 
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internalised by the caveolae-route. The authors also performed fluorescence co-localisation 
studies in which they observed a lower degree of lysosome-MOF co-localisation for the 
bigger nanoparticles, correlating well with the proposed endocytosis routes. 
 
Further studies on the UiO-66 isoreticular series examined the effect of particle size and 
linker substitution, which modifies the external surface chemistry presented by the particles, 
on endocytosis efficiency and routes [118]. UiO-66 again tended to favour clathrin-mediated 
endocytosis with minor contributions from macropinocytosis and caveolae-mediated 
endocytosis at larger sizes, although the smallest sample (ca 50 nm) was internalised by 
clathrin- and caveolae-independent endocytosis mechanisms (Figure 17a). Functionalised 
MOFs with more polar surfaces, such as UiO-66-NH2 and UiO-66-NO2, were taken up by 
HeLa cells in greater quantities, as determined by FACS using calcein-loaded nanoparticles. 
These more polar MOFs were predominantly internalised by clathrin-mediated endocytosis, 
in contrast to less polar, unfunctionalised materials (e.g. UiO-67), which had lower overall 
uptake, but primarily by caveolae-mediated endocytosis (Figure 17b). 
 
 
 
Figure 17. Cell internalisation routes of calcein loaded MOFs as determined by FACS for a) different 
sized nanoparticles of UiO-66 (Zr-L1) and b) nanoparticles of members of the isoreticular UiO-66 
series. Modified with permission from ref [118] copyright (2017) American Chemical Society. 
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Fairen-Jimenez et al. reported the HeLa cell internalisation routes of NU-1000 and compared 
it to amorphised NU-901 [112]. Whilst pristine, calcein loaded NU-1000 was taken up 
primarily by clathrin-mediated routes, with potentially a small contribution by caveolae-
mediated uptake, the amorphised sample showed a more significant decrease in cellular 
fluorescence when incubated with nystatin but also with chlorpromazine, suggesting 
caveolae-mediated uptake with some contribution from clathrin-mediated endocytosis. The 
authors also visualised cell internalisation and intracellular location of the MOFs using 
structured illumination microscopy (SIM), finding the NMOFs to be located mainly at 
vesicles. They observed that NMOFs start to be internalised after one hour, increasing the 
uptake gradually up to 24 h. 
 
Changes in particle surface chemistry will tune interactions with cells, and so we have 
investigated the HeLa cell endocytosis routes of UiO-66 after postsynthetic decoration with a 
variety of surface functionalities [73, 74]. MOFs functionalised with polymer chains by the 
click modulation protocol were very sensitive to the nature of the polymer. cal@UiO-66-L1-
PolyLact and cal@UiO-66-L2-PNIPAM were more efficiently internalised by HeLa cells 
compared to bare UiO-66, but no remarkable inhibition of mediated uptake routes was found 
while high suppression of cell uptake occurred upon sucrose pre-treatment, indicating that 
both might be internalised through clathrin- and/or non-mediated routes. Postsynthetic 
surface PEGylation resulted in enhanced uptake, while significant caveolae-mediated 
endocytosis was observed only for cal@UiO-66-L1-PEG2000 compared to cal@UiO-66-L1-
PEG550, meaning that the length of the PEG chains determines endocytosis pathways. 
 
Postsynthetic coating with folic acid resulted in internalisation of cal@UiO-66-FA by HeLa 
cells through the caveolae-mediated route. This is so because HeLa cells overexpress the 
folate receptor (FR), which is mainly located in the caveolae invaginations [130]. Hence, 
UiO-66 cell internalisation was remarkably higher after folate coating compared to the bare 
MOF, due to folate targeting, and no notable clathrin-mediated uptake for internalisation of 
folate-coated MOFs was observed. Heparin coating also promoted caveolae-mediated cell 
internalisation of UiO-66, although clathrin-mediated route plays an important role on its cell 
uptake. A related study with folate coated PCN-224-FA showed that its internalisation by 
HeLa cells decreases when an excess of free folate was added, as a consequence of free 
folate biding to the FR, thus decreasing uptake and suggesting cell internalisation occurs 
through receptor-mediated endocytosis, although the specific uptake routes were not studied 
[83]. Folate-mediated endocytosis has also been proposed as the major route of 
internalisation of UiO-66-NH2-FA-5-FAM, as HepG2 cells, which overexpress the FR, 
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display strong green fluorescence after incubation with the folate-coated MOF (0.1 mgmL-1 
for 2 h), while HL-7702 human liver cells, which do not overexpress the folate receptor 
display no green fluorescence under the same conditions. In addition, HepG2 cells 
incubated with UiO-66-NH2-5-FAM, i.e. without folate coating, show no appreciable green 
fluorescence [94]. 
 
The endocytosis pathways of Zr-fum-H6-GFP have been studied using the inherent 
fluorescence of the his-tagged green fluorescent protein. The cells were pre-incubated for 30 
minutes with different concentration of the various inhibitors – in this case amiloride to 
suppress macropinocytosis [131], genistein to inhibit caveolae-mediated endocytosis [132], 
and chlorpromazine to inhibit clathrin-mediated uptake – and then incubated with the 
NMOFs for 2 h. Using different concentrations of inhibitors allows assessment of dose-
responsive inhibition to confirm the importance of the inhibited uptake route (Figure 18). The 
authors found that the peptide-coated NMOFs are mainly internalised by macropinocytosis, 
although minor contributions of the caveolae-mediated route is also observed. In general, 
higher levels of inhibition were found when cells were pre-treated with higher concentration 
of the inhibitors.  
 
 
 
Figure 18. Cellular uptake of Zr-fum coated with his-tagged green fluorescent protein in the presence 
of different inhibitors as measured by flow cytometry. Reproduced with permission from ref [85] 
copyright (2017) American Chemical Society. 
 
Control of surface chemistry is clearly required to enhance endocytosis efficiency, but also to 
alter uptake pathways, whether by mimicking the chemistry of certain receptor sites (e.g. by 
PEGylation) or by directly targeting (e.g. folate receptors). Uptake by immune cells is also of 
great importance when considering an in vivo treatment, but examples of MOF 
internalisation by macrophages in the literature are relatively rare, and further work is clearly 
needed to understand this process and enhance NMOFs potential as DDS, by improving 
their uptake by cancerous cells while reducing immune cell recognition. Considering the 
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amount of work into studying and enhancing cell internalisation of Zr MOFs by endocytosis 
processes, there is very little research into determining and understanding the exocytosis 
processes, which may also play an important role in their therapeutic efficiency. The 
exocytosis of other nanoparticulate materials has been studied in vitro, and shown that it 
tends to occur for longer incubation times, especially if the nanoparticles present in the 
incubation media are removed [133]. Being able to extend the time that the nanoparticles are 
present inside cells, or suppressing exocytosis processes while enhancing endocytosis 
processes, could be of vital importance to enhance the therapeutic effect of MOF-based 
systems.  
 
 
6.3. Biocompatibility of Zr MOFs 
 
The therapeutic efficiency of any DDS is strictly correlated to its ability to cross the cell 
membrane and successfully deliver the drug to the various cell compartments. As described 
in the previous sections, both cell internalisation rates and routes are of crucial importance 
for efficiency drug delivery, as well as low toxicity of the DDS and its ability to deliver active 
cargo into cells. Typically, in vitro cell proliferation experiments, such as (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) 
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays after 
incubation of cells with the DDSs, are used as key initial evaluators of the effect of factors 
such as surface modification and drug loading.  
 
It is important to note that comparisons between absolute values for cell proliferation 
determined from different laboratories can be significantly affected by experimental 
parameters such as MOF particle size, morphology, preparation method, residual solvent, 
and other variables such as the age of cells and how many times they have been passaged. 
For example, HeLa cells are known to mutate, and hence results might drastically differ 
between passages and labs [134]. Half inhibitory concentration (IC50) values for the 
archetypal Zr MOF UiO-66 towards HeLa cervical cancer cells have been variously 
measured to be 1.50 ± 0.15 mgmL-1 (261 ± 12 nm, HCl modulation, MTS assay, 24 h 
incubation) [110], 0.40 ± 0.01 mgmL-1 (100 ± 20 nm, HCl modulation, MTT assay, 24 h 
incubation) [135], and >1 mgmL-1 (77 ± 24 nm, DCA modulation, MTS assay, 72 h 
incubation) [74]. Nevertheless, these are still relatively high concentrations compared to 
expected clinically relevant doses. UiO-66, UiO-66-NH2 and UiO-67 have also been found to 
be compatible with MCF-7 breast cancer cells up to 0.2 mgmL-1, but of the trio, UiO-66-NH2 
was found to be somewhat cytotoxic towards HepG2 liver cancer cells at this concentration 
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[50]. The amino groups are expected to be protonated under physiological conditions; the 
more efficient internalisation of positively charged nanoparticles by cells, due to the negative 
potential of the cell membrane [114], could be one of the reasons why the cytotoxicity is 
more pronounced. ZJU-800 has also been proven non-cytotoxic in rat neuroblastic 
pheochromocytoma PC12 cells after incubation with a solution of 0.1 mgmL-1 of NMOF for 
24 h [111]. 
 
The biocompatibility of empty Zr MOFs has also been investigated before and after surface 
modifications. For example, the effect of UiO-66-NH-Q and capped UiO-66-NH-Q-Cp5 in 
HEK293 normal human kidney cells has been assessed using the MTT protocol, incubating 
cells with concentrations of NMOF from 3 to 50 µgmL-1 [93, 99]. Cell proliferation started to 
decrease when treated with a 25 µgmL-1 solution of UiO-66-NH-Q, while no effect on cell 
viability was observed after Cp5 capping for concentrations of MOF up to 50 µgmL-1, again 
possibly as a consequence of the positive charges of amine-terminated UiO-66-NH-Q.  
 
The biocompatibility of bare PCN-223 towards SMMC-7721 human hepatocellular carcinoma 
and HeLa cells was enhanced after PBLs coating [90], with nanoPCN-223@DOPC/DOPC 
being non-cytotoxic at concentrations of 0.4 mgmL-1, while treatment with the same 
concentration of bare MOF decreased cell viability to ~70%, even though its cell 
internalisation efficiency is lower than for the coated MOF. A number of other Zr MOFs have 
been tested for in vitro biocompatibility as part of greater investigations into therapeutic 
activity (both photodynamic and through drug delivery) and will be described in the following 
sections. 
 
 
6.4. Photodynamic Therapy with Zr MOFs 
 
Photodynamic therapy (PDT) is based on the use of a photosensitizer that, after excitation 
with light, can transfer its excited state to neighbouring oxygen resulting in the generation of 
singlet oxygen (1O2) and reactive oxygen species (ROS), killing surrounding cells. Among 
sensitizers, porphyrin molecules have proven to be some of the most efficient. Hence, their 
incorporation into MOFs can result in targeted accumulation, which is necessary for selective 
cytotoxicity, and an enhancement of their therapeutic effect. Aggregation-based quenching is 
known to be one of the major problems that reduces generation of singlet oxygen species, 
and incorporation of sensitizers into MOFs has been proposed as an alternative to reduce 
this quenching effect, while favouring diffusion of singlet oxygen species out of the MOF 
matrix [35, 36]. A number of examples of Zr-MOFs as PDT agents have emerged recently, 
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mostly involving porphyrin-based samples, and showing very promising results that are 
represented in Table 5.  
 
Table 5. Examples of Zr MOFs used for PDT. 
Sample 
Light Source 
(mWcm
-2
) 
Cell Lines 
Time 
(min) 
PDT Efficacy Ref 
UiO-PDT Visible light (80) 
CT26, C26 
B16F10 
10 
CT26 IC50= 0.70 µgmL
-1
; 
C26 IC50 = 1.15 µgmL
-1
; 
B16F10 IC50 = 0.51 µgmL
-1
 
[100] 
PCN-224 
PCN-224-FA 
Laser, 420 nm 
and 630 nm (100) 
HeLa, A549 30 
2-fold increase compared to linker; 
Folate-targeting of HeLa cells 
[83] 
ZnDTPP-I2@UiO-66 
Green LED, 540 
nm (20) 
HepG2 10 
<50% proliferation at 10 µgmL
-1
 MOF; 
<25% proliferation at 40 µgmL
-1
 MOF 
[79] 
UiO-66-TPP-SH 
UiO-66-TCPP 
Laser, 660 nm 
(100) 
HeLa 10 
UiO-66-TPP-SH higher phototoxicity 
than UiO-66-TCPP and free TPP-SH 
[80] 
PCN224-UCNP 
Laser, 980 nm, 
(15900) 
MB-MDA-462 10, 20 
<20% proliferation at 100 gmL
-1
 
targeted MOF 
[136] 
Mn-doped 
UiO-66-PEG 
MW Irradiation HepG2 2 25% proliferation at 62 µgmL
-1
 MOF [96] 
 
It is important that the PDT system only induces cytotoxicity under irradiation to limit off-
target effects. UiO-PDT, coated with a bodipy chromophore, induced no cytotoxicity towards 
mouse colon carcinoma C26 cells, murine colon carcinoma CT26 cells, and B16F10 mouse 
melanoma cells when incubated for 24 h at concentrations up to 1 mgmL-1 in the dark [86]. 
As UiO-PDT can generate 1O2 under light irradiation (Figures 19a and 19b) with similar 
efficiencies to I2-BDP (the free linker), determined by measurement of the degradation of 
1,3-diphenylisobenzofuran (DPBF) by UV-Vis spectroscopy, the in vitro phototoxicity of UiO-
66-PDT (0-0.625 mgmL-1) could be assessed using the MTT assay with CT26, C26 and 
B16F10 cells (Figures 19c and 19d).  
 
The authors observed that free I2-BDP has IC50 >15 µgmL
-1 in the dark, which decreases to 
IC50 < 0.8 µgmL
-1 when irradiated at a power density of 80 mWcm−2 for 10 min under visible 
light for the studied cell lines. UiO-PDT has similar cytotoxicity values to free I2-BDP under 
light irradiation, with IC50 values of 0.70, 1.15 and 0.51 μgmL
−1 for B16F10, CT26 and C26 
cells, in turn, despite the higher cell internalisation of UiO-66-PDT compared to I2-BDP, as 
determined by FACS. The fact that I2-BDP is present at 30% loading in UiO-PDT, coupled 
with the free bodipy molecule potentially undergoing passive diffusion and thus being located 
in the cytoplasm rather than in vesicles, might be the reason why there is not a more 
pronounced cytotoxic effect when cells are incubated UiO-PDT, together with the fact that 
free linker has a slightly better ability to generate 1O2.  
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Figure 19. UV/Vis spectroscopic measurement (degradation of DPBF) of singlet oxygen (
1
O2) 
generation by UiO-PDT in DMF (LED, 20 mWcm
–2
, 60 s). (b) Quantification of 
1
O2 generation ability 
showing the degradation of DPBF over time: DPBF control, DPBF in the presence of UiO-PDT, and 
free I2-BDP after light irradiation. (c) In vitro cytotoxicities (MTT assay) of free I2-BDP and UiO-PDT 
towards B16F10 cells before and after light irradiation (visible light, 80 mWcm
–2
, 10 min). (d) IC50 
values of I2-BDP and UiO-PDT with and without light irradiation for different cell lines. Modified with 
permission from ref [86] copyright (2016) The Royal Society of Chemistry. 
 
The potential of five samples of PCN-224 of different particle sizes as PDT devices was also 
tested on HeLa cells, and therapeutic efficiency was consistent with the cell uptake results 
[83]. Particles of 90 nm size, which were the most efficiently internalised size fraction, were 
also the most cytotoxic under light irradiation (laser, 420 nm and 630 nm), while no 
remarkable effect on cell proliferation was found in dark. PCN-224 exhibits a two-fold 
increase in cytotoxicity compared to the free TCPP linker, suggesting that incorporation into 
the MOF scaffold enhances efficiency. HeLa cells overexpress the folate receptor, and thus 
coating the MOF with folic acid resulted in an enhancement of the therapeutic efficiency of 
PCN-224-FA in comparison to the unmodified MOF. A control experiment, in which FR 
negative cells (human lung carcinoma A549 cells) were treated with PCN-224-FA and bare 
PCN-224 was performed, showing no enhancement in either cell internalisation or PDT 
efficacy upon folate coating.  
 
Zn-TDPP-I2@UiO-66 was found to have higher 
1O2 production efficiency than an analogous 
sample without iodine atoms, attributed to the heavy atom effect. Importantly, the Zn-TDPP-
I2 doped MOF exhibited higher 
1O2 generation than free Zn-TDPP-I2. In vitro PDT against 
HepG2 liver cancer cells was investigated by the MTT cell proliferation assay. Zn-TDPP-
I2@UiO-66 was proven biocompatible, with ~87% cell viability when cells where treated with 
60 µg/mL in dark, while a remarkable decrease in cell proliferation was found upon LED light 
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irradiation ( = ~540 nm), with 50% cell viability for a concentration of 10 µgmL-1 of MOF, 
and less than 25% at a concentration of 40 µgmL-1 [79]. 
 
UiO-66 surface functionalised with a thiol-modified porphyrin, UiO-66-TPP-SH, was 
postulated to increase therapeutic efficiency based on the fact that ROS are highly reactive 
and have short half-lives [80]. Therefore, PDT can only directly and efficiently affect the cells 
that are proximal to the ROS producing area, and so location of the photosensitizer on the 
external surface of NMOFs might be a key factor to enhance PDT efficiency. In fact, 1O2 
generation by UiO-66-TPP-SH was more efficient than for the porphyrin (TPP-SH) alone 
(Figures 20a and 20b), indicating that surface-decorated TPP-SH on the MOF surfaces were 
well separated, and their agglomeration and self-quenching of the excited states were 
effectively avoided. Additionally, UiO-66-TPP-SH has higher 1O2 generation than an 
analogous sample TCPP@UiO-66, in which TCPP was trapped in the core of the structure 
during synthesis; TCPP located inside the matrix might be inefficient due to singlet oxygen 
diffusion issues. 1O2 generation inside HeLa cells under laser irradiation (Figure 20c) was 
assessed by the 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) assay and found to 
correlate well with the UV/Vis spectroscopic analysis. 
 
MTT assays (0-15 µgmL-1 MOF and 0-0.56 µgmL-1 of equivalent porphyrin, Figures 20d and 
e) confirmed the MOF to be biocompatible with no cytotoxicity in the dark. In agreement with 
1O2 generation efficiency, a decrease in proliferation of ~70% occurred upon light irradiation 
(100 mW for 10 min) after incubation with 15 µgmL-1 of UiO-66-TPP-SH, while UiO-66-TCPP 
displayed a decrease of only ~41% under the same conditions. TPP-SH had no dark 
cytotoxicity and, even at high concentrations of 5 µgmL-1, only decreased cell proliferation by 
12% under light irradiation, highlighting the enhancement in its phototoxicity when attached 
to the external surface of UiO-66 [80]. 
 
46 
 
 
 
Figure 20. a) Time-dependent UV/Vis spectroscopic measurement (degradation of DPBF) of 
1
O2 
generation by UiO-66-TPP-SH in DMF (2.5 μM porphyrin equiv, 660 nm laser, 20 mWcm
–2
, 60s). b) 
Comparison of DPBF degradation, a consequence of 
1
O2 generation, by TPP-SH (2.5 μM), TCPP (2.5 
μM), UiO-66-TPP-SH (2.5 μM porphyrin equiv), and TCPP@UiO-66 (2.5 μM porphyrin equiv) 
compared to a control of free DPBF. c) Intracellular 
1
O2 generation induced by TPP-SH (15 μgmL
-1
, 
18 μM porphyrin equiv), TCPP@UiO-66 (15 μgmL
-1
, 0.56 μM porphyrin equiv), and UiO-66-TPP-SH 
(15 μgmL
-1
, 0.56 μM porphyrin equiv) in HeLa cells (660 nm, 100 mWcm
−2
, 5 min) using 2′,7′-
dichlorodihydrofluorescein diacetate (DCFH-DA) assay. Scale bar = 50 μm. HeLa cell proliferation 
(MTT assay) for 2 h incubation with UiO-66, TPP-SH, TCPP@UiO-66, and UiO-66-TPP-SH d) without, 
and e) with irradiation (660 nm laser, 100 mWcm
−2
, 10 min). Modified with permission from ref [80] 
copyright (2018) American Chemical Society. 
 
Inorganic units have also been incorporated to Zr MOFs for PDT. PCN-224 was surface 
modified with DNA strands by a sequential coordination / amide coupling / SPAAC protocol, 
and the single strands were hybridised with complementary sequences to attach 
NaFY4:Yb/Er upconverting nanoparticles (UCNPs) to give PCN-224-UCNP [136]. The hybrid 
was found to generate 1O2 under near-infrared (NIR) irradiation (laser,  = 980 nm, 500 mW, 
15.9 Wcm−2) using the fluorescent Singlet Oxygen Sensor Green assay, with increasing 
ratios of UCNP to MOF increasing 1O2 generation. The MOF was subsequently PEGylated 
with thiol-modified PEG2000, and MTT assays showed that MB-MDA-468 human breast 
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cancer cell proliferation was not negatively affected up to concentrations of 150 gmL-1. 
Assessment of PDT efficiency was carried out on the same cells after incubation with 100 
gmL-1 of MOF for 4 h, followed by NIR laser irradiation for 10 or 20 min, and a further 12 h 
incubation. MTT assays showed no adverse effect from MOFs without UCNPs, with or 
without irradiation, but PCN-224-UCNP samples showed 50-60% decreases in proliferation 
after irradiation, with irradiation time not significantly affecting the results. Further increases 
in PDT efficiency (70-80% decrease in proliferation) could be achieved by attaching 
epidermal growth factor receptor affibodies – small targeting proteins – to the free amines of 
the UCNPs through succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate groups 
on the affibodies, demonstrating the power of the targeting approach.  
 
Whilst PDT uses electromagnetic irradiation to generate ROS that kill surrounding cells, an 
example has also been shown to use microwave (MW) irradiation to promote their formation. 
Mn-doped UiO-66-PEG was studied for microwave dynamic therapy and for microwave 
thermal therapy [96]. While no increase in temperature was found in water containing the 
MOF after irradiation (1.8 W, 450 MHz) for 5 min, the temperature of NaCl solution (0.9%) 
containing the MOF rose rapidly, meaning that ions play a key role in the increase of 
temperature under MW irradiation, probably due to the strong inelastic collision between ions 
and the framework. The MOF showed peroxidase-like activity, catalysing the conversion of 
H2O2 to 
OH under MW irradiation, increasing with both irradiation time and MOF and H2O2 
concentrations, whereas controls without MOF show no OH generation.  
 
Infrared thermal imaging was used to monitor the temperature of HepG2 cells during the 
MTT cell proliferation assay, showing an increase to 45 °C after 2 min at MW irradiation of 
0.9 W when cells are incubated with 62 µgmL-1 of MOF. After 24 h of MOF incubation (63 
µgmL-1) with HepG2 cells without MW irradiation, 80% cell proliferation was observed, 
demonstrating good biocompatibility, while incubation with the same concentration of MOF 
under MW irradiation resulted in only ~25% cell proliferation. A control in which cells were 
immersed in a water bath at 45 °C resulted in cell proliferation of >80%, suggesting that the 
cytotoxic effect is due to incubation with the MOF under mild MW irradiation. To elucidate 
the mechanism, the authors used 2,7-dichlorofluorescein diacetate (DCFH-DA), a reactive 
oxygen species index probe that can be oxidized in the presence of ROS and exhibits green 
fluorescence upon excitation at 520 nm. Quantification of hydroxyl radicals in HepG2 cells 
with or without irradiation upon incubation with the MOFs was performed, showing indeed 
that cytotoxicity is a result of ROS generation upon incubation with the MOF under MW 
irradiation. Control groups showed no fluorescence, and only a small green fluorescence 
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signal was found in the control of MOF without irradiation, while strong fluorescence was 
observed in the cell treated the MOF and irradiation.  
 
 
6.5. Drug Delivery from Zr MOFs 
 
The biocompatibility of Zr-MOFs, combined with their high storage capacities, excellent 
stabilities and controlled release of cargo, has led to many reports into both in vitro and in 
vivo anticancer activity. As a first port of call, the efficiency of therapeutic cargo delivery into 
cells is monitored in vitro, often by comparing cell proliferation in the presence of the drug-
loaded MOF with that of the free drug and the empty MOF. A summary of the most relevant 
in vitro studies carried out with Zr MOFs is given in Table 6.  
 
The therapeutic efficiency of UiO-66-AL, coated on its surface with the drug alendronate, 
was tested in human breast cancer MCF-7 and human liver carcinoma HepG2 cells using 
the MTT assay [84]. The authors found that after 24 h of incubation, the free drug had a 
higher effect than the loaded NMOFs, while after 48 h, incubation with UiO-66-AL decreased 
cell proliferation to a slightly higher extent than when cells were treated with a solution of the 
same free drug concentration (Figures 21a-c). These results could indicate slow uptake of 
the MOF or particles reaching different intracellular locations after different time periods, but 
it is also important to consider that if the MOF itself degrades during the incubation time, the 
free drug subsequently present in the growth media could then be internalised through 
passive diffusion and thus inhibit cancer cell growth. 
 
α-Cyano-4-hydroxycinnamic acid (α-CHC) has been proposed as an anticancer drug [137], 
and can be loaded postsynthetically into Zr MOFs. An investigation of the delivery of α-CHC 
into HeLa cells by UiO series MOFs showed that cell proliferation was dependent on the 
endocytosis pathways of the MOFs [105]. As UiO-66 is internalised through clathrin-
mediated endocytosis, α-CHC@UiO-66 (31% w/w α-CHC loading) did not have a negative 
effect on HeLa cells after incubation for 24 h, but as UiO-67 partially undergoes caveolae-
mediated endocytosis, incubation with α-CHC@UiO-67 (20% w/w α-CHC loading, 0.25-1 
mgmL-1) decreased cell proliferation to <70% for the concentrations studied, while the empty 
MOF was non-cytotoxic.  
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Figure 21. Cell proliferation assays (MTT) for a) HepG2, and b) MCF-7 cells after incubation with free 
alendronate (AL) and AL@UiO-66. Modified with permission from ref [84] copyright (2014) The Royal 
Society of Chemistry. c) Chemical structure of alendronic acid with its coordinating units highlighted. 
Cell proliferation assays (MTS) for HeLa cells after incubation with free -cyanohydroxycinnamic acid 
(-CHC) and -CHC@NU-1000 before and after thermal amorphisation for d) 8 h, and e) 48 h. 
Modified with permission from ref [112] copyright (2017) American Chemical Society. f) Chemical 
structure of -CHC with its coordinating units highlighted. 
 
Due to the larger porosities of NU-1000 and NU-901, α-CHC loadings of up to 81% w/w 
have been reached. The therapeutic effect in HeLa cells of α-CHC loaded NU-1000 and NU-
901 before and after amorphisation through temperature treatment was studied using the 
MTS assay and compared to a control in which the cells were incubated with a solution of 
the same concentration of free drug [112]. Although both α-CHC@NU-1000 and α-CHC@tt-
NU-1000 induce higher cell cytotoxicity than the free drug, there is no real difference 
between pristine and amorphised MOF after 8 h incubation. The enhancement in cytotoxicity 
compared to the free drug could be a consequence of its greater internalisation when loaded 
in the DDS compared to passive diffusion, and to the internalisation of the MOF through 
caveolae-mediated endocytosis, enabling endosomal escape. After 48 h of incubation time a 
notable difference upon temperature treatment was found, especially for lower 
concentrations of the temperature-treated NU-1000. While the free drug and α-CHC@NU-
1000 did not induce any cytotoxicity up to 0.6 mgmL-1 drug concentration, cell proliferation 
decreased to ~80% for 0.2 mgmL-1 α-CHC loaded in thermally treated NU-1000, while α-
CHC@tt-NU-1000 killed all cells at a drug concentration of 1.60 mgmL-1 of drug (Figures 
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21d-21f). Similar behaviour is observed for α-CHC@NU-901 and α-CHC@tt-NU-901, which 
have the same effect on HeLa cell viability after 11 h of incubation, again showing 
considerably more cytotoxicity than the free drug, while after 48 h of treatment, the efficacy 
of the thermally treated sample difference is more pronounced at lower concentrations. The 
authors also used structured illumination microscopy (SIM) to visualise cellular uptake of 
calcein loaded MOFs in real time. 
 
Table 6. Examples of in vitro drug delivery from Zr MOFs. 
MOF Drug Loading Cell line Drug Delivery Efficacy Ref 
UiO-66-AL 
AL  
51.4% w/w 
MCF-7  
HepG2  
Higher cytotoxicity than the free 
drug  
[84] 
NU-1000 
NU-901 
α-CHC 
 ~81% w/w 
HeLa 
Higher cytotoxicity than the free 
drug; 
Enhancements from thermal 
amorphisation 
[112] 
UiO-66-X 
DUT-52 
UiO-67 
α-CHC  
~30% w/w 
HeLa 
Cytotoxicity accordingly with 
endocytosis routes of 
internalisation 
[105] 
UiO-66 
UiO-66-Hep 
UiO-66-Biot 
DCA  
10-20% w/w 
HeLa 
 
No cytotoxicity, related to 
endocytosis studies 
[74] 
UiO-66-FA 
UiO-66-L1-PolyLact 
UiO-66-L1-PEG2000 
UiO-66-L2-PNIPAM 
DCA  
10-20% w/w 
HeLa 
MCF-7 
HEK293 
J774 
Human lymphocytes 
Higher anticancer efficiency 
than the free drug;  
Surface dependent selective 
anticancer cytotoxicity related to 
endocytosis routes 
[73], [74] 
UiO-66-X 
DUT-52 
UiO-67 
DCA  
~7-26% w/w 
MCF-7 
Higher anticancer efficiency 
than the free drug related to 
endocytosis routes  
[78] 
UiO-66-X 
DUT-52 
UiO-67 
DCA ~7-26% w/w; 
5-FU ~1-4% w/w 
MCF-7 
Synergistic DCA and 5-FU 
enhanced cytotoxicity; 
Cytotoxicity related to 
endocytosis routes 
[78] 
UiO-66-NH2-FA-5-FAM 
5-FU 
Up to 26% w/w 
HepG2 
No apparent enhancement in 
cytotoxicity compared to the 
free drug 
[94] 
Zr-fum-H6-Tags 
(Bak, Bad, KLK) 
Cytc 
Pro-apoptosis 
peptides 
Cytochrome c 
protein 
HeLa 
Higher cytotoxicicty than free 
peptides 
[85] 
siRNA-UiO-Cis 
siRNA; 
Cisplatin  
12.3% w/w 
SKOV-3 
MCF-7  
H460 
A2780  
siRNA gene silencing; 
Enhanced cytotoxicity towards 
cis-platin resistant cell lines 
[87] 
UiO-68-N3-DNA 
conjugates 
DOX 
52.8 μmols 
DOX·per gram of 
MOF 
MDA-MB-231 
MFC-10A  
Higher anticancer efficiency 
than the free drug; 
 Stimuli-responsive cytotoxicity 
towards cancer cells; 
Nucleolin targeting enhances 
cytotoxicity 
[98] 
Zr89UiO-66-Py-PGA-
PEG-F3 
DOX 
50% w/w 
MDA-MB-231 
L929 
Enhanced cytotoxicity by 
nucleolin targeting (F3 peptide) 
[100] 
DOX@ 
Fe3O4@UiO-66-NH2 
DOX 
HeLa 
3T3  
Selective anticancer cytotoxicity [141] 
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We have investigated the therapeutic efficiency of a series of surface functionalised UiO-66 
MOFs where the anticancer probe molecule, dichloroacetic acid (DCA), can been loaded 
during synthesis by using it as a modulator [73]. As DCA is a pyruvate dehydrogenase 
kinase inhibitor, it is only cytotoxic if it can cross the cell membrane and reach the cytosol, 
hence it is an excellent probe molecule for drug delivery from MOFs, as its IC50 value is the 
milimolar range, and therapeutic enhancement will indicate good cellular internalisation. 
Additionally, defect incorporation of drugs during synthesis is a protocol that is also 
compatible with further drug loading or surface functionalisation. Initially, it was found that 
the change in HeLa endocytosis pathway induced by PEGylation of UiO-66 meant that 
DCA@UiO-66-L1-PEG2000, which is internalised by caveolae-mediated endocytosis, 
decreased HeLa cell proliferation to ~50% when incubated with 1 mgmL-1 MOF, whereas 
DCA@UiO-66, which is internalised by clathrin-mediated endocytosis, had no effect. The 
efficacy of the intracellular delivery of DCA is highlighted by the fact that the IC50 of the free 
drug is close to 3 mgmL-1 [138], yet delivery of ~0.1 mgmL-1 DCA in DCA@UiO-66-L1-
PEG2000 induces significant cytotoxicity. 
 
The surface chemistry of the MOF can also be modified by linker functionalisation. An 
isoreticular series of Zr MOFs with different linkers were prepared by DCA modulation; only 
minor cytotoxic effects towards MCF-7 breast cancer cells were found for DCA@UiO-66-Br 
and DCA@UiO-66-NO2, whereas DCA@DUT-52 and DCA@UiO-67 were the most 
therapeutically efficient MOFs despite their lower DCA content, suggesting that caveolae-
mediated endocytosis, which plays a more important role for the latter two MOFs, enhances 
cytotoxicity (Figure 22a). DCA@UiO-66-NH2 also showed high therapeutic efficacy, possibly 
as a consequence of the positive charge of the pendant amino groups under physiological 
conditions. Decreasing particle size from ~150 nm to ~15-25 nm can further enhance 
cytotoxicity somewhat, possibly due to passive diffusion of nanoparticles into cells, but not to 
the same extent as control of surface chemistry [78]. 
 
We have also examined the effect of different polymer coatings of UiO-66 across additional 
cell lines; MCF-7 breast cancer cells, HEK293 human embryonic kidney cells, J744 
macrophages and peripheral blood lymphocytes isolated from the blood of human donors 
[74]. Similar trends to the HeLa experiments were observed when MCF-7 cells were treated 
with the bare and PEGylated DCA@UiO-66, but DCA@UiO-66-L1-PEG2000 induced 
unwanted cytotoxicity to human embryonic kidney HEK293 cells at high doses, without any 
remarkable negative effects on macrophage or lymphocyte proliferation. Empty UiO-66 
coated with thermally-responsive PNIPAM was found to be cytotoxic against HeLa cells at 
concentrations of MOF of 0.5 mgmL-1 during 72 h of incubation, although empty poly-L-
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lactide coated UiO-66 was biocompatible up to 1 mgmL-1. Despite both DCA-loaded samples 
reducing the proliferation of both cervical and breast cancer cells, they were found to be 
cytotoxic also for HEK293 kidney cells. Both DCA@UiO-66-L1-PolyLact and DCA@UiO-66-
L2-PNIPAM induced cytotoxicity and ROS production in J774 macrophages and human 
peripheral blood lymphocytes, suggesting incompatibility with the immune system. 
Interestingly, none of the empty samples had notable negative effects on cell growth and 
ROS production, indicating that it is the synergic effect of the polymers surface coating and 
DCA which induces cells cytotoxicity, and that the surface coating must be carefully selected 
to avoid unwanted off-target effects.  
 
 
 
Figure 22. Cell proliferation assays (MTS, 72 h) for a) MCF-7 cells incubated with DCA-loaded 
members of the UiO-66 isoreticular series, ranked by delivered DCA concentration, b) DCA5@UiO-66-
FA1 (CM) incubated with HeLa, MCF-7 and HEK293 cells, showing selective anticancer cytotoxicity, 
and c) MCF-7 cells incubated with DCA- (coordination modulation) and 5-FU- (postsynthetic) loaded 
UiO-66 isoreticular series MOFs, ranked by delivered 5-FU concentration and compared to free 5-FU. 
Modified with permission from ref [78] copyright (2018) The Royal Society of Chemistry and ref [74] 
copyright (2017) American Chemical Society. 
 
Functionalising nanoparticles with targeting units can increase their cellular uptake 
efficiencies and direct DDSs to specific sites of disease, potentially reducing off-target 
effects. We have assessed different methods of functionalising UiO-66 with folic acid, which 
is a known targeting strategy for several cancers, incorporating folate both during synthesis 
and postsynthetically [74]. After 72 h of incubation the empty folate coated MOFs did not 
induce any negative effect on HeLa cell proliferation up to 1 mgmL-1 of NMOF, while DCA-
loaded, folate-coated MOFs have different dose-responsive effects on cell viability, related to 
the DCA and folate contents and the stability of the samples. Samples prepared by 
postsynthetic folate coating of DCA@UiO-66 were less cytotoxic towards HeLa cells, 
possibly due to free folate being released from the MOF during the incubation time and 
binding to the folate receptor expressed on the surface of cancer cells, thus decreasing MOF 
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uptake. Samples prepared in a one-pot synthesis where folic acid and DCA act as 
modulators tended to be more cytotoxic, since folic acid can be attached to the Zr clusters in 
the defect sites in the core of the structure as well as at the surface. The power of folate 
targeting was evident in the fact that DCA5@UiO-66-FA1 (CM), which has a higher folate 
coating and a lower DCA content, induced more cytotoxicity, despite containing less DCA 
than DCA10@UiO-66-FA0.25 (CM), which has a higher DCA content and a lower folate 
coating. 
 
The most efficient sample, DCA5@UiO-66-FA1 was also tested against the MCF-7 cell line, 
which has a lower overexpression of the FR compared to HeLa cells [139], and cell growth 
was inhibited to lesser extent compare to HeLa cells (Figure 22b). DCA5@UiO-66-FA1 was 
biocompatible with HEK293 cells up to 1 mgmL-1 of NMOF over 72 h of incubation, while 
both empty and DCA-loaded UiO-66-FA were found to be non-cytotoxic towards J774 
macrophages and human peripheral blood lymphocytes over 48 h, not generating significant 
ROS production, and thus confirming the efficiency of folate targeting and suggesting the 
validity of these DDSs for in vivo treatment. 
 
The use of DCA as a modulator results in UiO-66 nanoparticles loaded with DCA at defect 
sites but with excellent porosity for postsynthetic storage of additional drugs. This dual-drug 
strategy was exploited to prepare 5-FU@DCA@MOFs, which were found to affect 
proliferation of MCF-7 cells much more significantly compared to their precursor 
DCA@MOFs [78]. Comparison of their effect on cell proliferation to free 5-FU showed 
surface chemistry dependence, following similar trends to the DCA precursors: 5-
FU@DCA@UiO-67 and 5-FU@DCA@DUT-52 (~200 nm) were the most cytotoxic, followed 
by 5-FU@DCA@UiO-66 and 5-FU@DCA@UiO-66-NH2, all of them significantly more active 
than free 5-FU, whereas 5-FU@DCA@UiO-66-NO2 had a similar effect on cell proliferation 
to 5-FU, and performance of 5-FU@DCA@UiO-66-Br was worse than the free drug (Figure 
22c). The UiO-66 derivative MOFs with electron withdrawing groups (Br, NO2) were 
significantly bigger (~30 nm) than UiO-66 and UiO-66-NH2 (~13 nm); the smaller NMOFs are 
more likely to undergo passive internalisation, and may explain their better efficacy. 
Importantly, although it has been reported that DCA enhances the effect of 5-FU on cancer 
cells, the DCA doses required to reach the synergistic effect are at least one order of 
magnitude higher than the maximum dose reached if the MOFs release their full cargo [140]. 
This suggests that co-delivery from one DDS is a valid strategy to boost anticancer activity, 
especially considering that controls in which 5-FU and DCA were incubated with cells, at 
concentrations delivered by the MOFS, resulted in no enhancement of 5-FU therapeutic 
efficiency.  
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A combination of folate-targeting and 5-FU delivery resulted in the preparation of 5-
FU@UiO-66-NH2-5-FAM-FA, surface functionalised by amide condensation reactions 
between the carboxylate groups of the fluorescein (5-FAM) and folic acid (FA) surface 
reagents. The MOF was proven to be biocompatible to human liver HL-7702 cells, with cell 
proliferation over 80% when treated with 0.2 mgmL-1 of MOF, while the empty MOF UiO-66-
NH2-5-FAM-FA and 5-FU exhibited a similar cytotoxic effect. The anticancer activity was 
assessed using HepG2 cells, in which incubation with 5-FU@UiO-66-NH2-5-FAM-FA had a 
slightly lesser effect than the same mass of the free drug (cell proliferation 57% vs 40%, 
respectively, at a concentration of 0.2 mgmL-1) despite the targeting effect. This is likely due 
to the maximum 5-FU loading being reported as 26% w/w for UiO-66-NH2, although no 
loading value for 5-FU@UiO-66-NH2-5-FAM-FA is given in the paper [94]. 
 
The potential of Zr-fum as a delivery vector for biomolecules was investigated by attaching 
various pro-apoptotic peptides (Bak, Bad, KLK) and a cytochrome c protein (CytC) which, 
due to their membrane impermeability, are not able to efficiently cross the cell membrane by 
themselves, to the NMOF surface using His-tags [85]. The authors observed a 20-fold 
increase in the mean cell internal fluorescence of HeLa cells when incubated with Zr-fum-
H6CF (H6CF = carboxyfluorescein with six histidine residues) and a 30-fold increase for Zr-
fum-H6GFP (H6GFP = green fluorescent protein modified with six histidine residues) 
compared to when cells were incubated with solutions of the same concentration of the 
respective free peptides in growth media, highlighting the efficiency of Zr-fum in internalising 
biomolecules not able to do so efficiently themselves. Thus, a decrease in HeLa cell viability 
when treated with the peptide-modified NMOFs was considered a consequence of efficient 
cytosolic release of the attached peptides. The authors compared the effect on cell growth to 
those obtained when incubating cells with free peptide or naked Zr-fum for the same period 
of time. The peptide or protein conjugated MOFs induced remarkably higher cytotoxicity on 
cells (~40% cell proliferation) compared with the free peptide (~90% cell proliferation), while 
naked MOF did not exhibit any cytotoxicity, confirming the intracellular delivery of the 
peptides by the MOF (Figures 23a and 23b).  
 
Lin and co-workers investigated siRNA transfection efficiency mediated by siRNA-UiO-Cis – 
UiO-68 functionalised with siRNA and loaded with cis-platin – in SKOV-3 ovarian cancer 
cells, which have cis-platin resistance. By siRNA delivery, the authors aimed to inhibit three 
genes (survivin, Bcl-2 and P-gp) in order to overcome cis-platin resistance. ELISA assays 
showed that when cells were incubated with siRNA-UiO-66-Cis (either as a pool of siRNA or 
with siRNA specific to inhibit certain genes) potent gene silencing was induced, while free 
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siRNAs on their own did not have the same effect, (Figure 23c), as naked siRNA 
degradation in biological media occurs quickly, determined by Western blot. These results 
were mirrored by the therapeutic effect, as when cells incubated with either UiO-Cis or free 
cis-platin plus a pool of free siRNA had a similar cytotoxic effect to the free drug on its own 
(cis-platin IC50= 53.9 ± 4.7, 53.2 ± 4.4 and 45.1 ± 7.0 µM for free cis-platin, UiO-Cis and free 
cis-platin/pool siRNA respectively), whereas when cells were incubated with siRNA-UiO-Cis 
or free cis-platin and siRNA-UiO, remarkably lower IC50 values (cis-platin IC50 = 4.7 ± 1.8 
and 6.6 ± 0.3 µM, in turn) were found, as a consequence of efficient siRNA delivery [87].  
 
 
 
Figure 23. MTS cell proliferation assays for delivery of his-tagged pro-apoptotic peptides into HeLa 
cells by Zr-fum for a) H6-Bak, and b) H6-Bad at 10 M peptide concentration. Modified with permission 
from ref [85] copyright (2017) American Chemical Society. c) Gene silencing in SKOV-3 cells 
assessed by decrease in protein expression as a result of delivery of 30 nM siRNA by siRNA-UiO-Cis 
compared to controls. Modified with permission from ref [87] copyright (2014) American Chemical 
Society. 
 
Importantly, no cytotoxicity was found for siRNA-UiO, confirming that it is the co-delivery of 
siRNA and cis-platin that induces cytotoxicity towards SKOV-3 cells. Experiments using cis-
platin sensitive cell lines, such as human ovarian carcinoma A2780, human breast 
carcinoma MCF-7 and human lung carcinoma H460 cells, demonstrated that both UiO-Cis 
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and siRNA-UiO-Cis had similar levels of cytotoxicity, strongly suggesting that siRNA and cis-
platin co-delivery using UiO-68 as a DDS could overcome cis-platin resistance of certain 
cancer cells through the combined effect of therapeutics and gene silencing. Through 
Annexin V conjugate staining and DNA ladder assays, siRNA-UiO-Cis induced cytotoxicity 
was proved to occur due to apoptosis rather than necrosis.  
 
The cytotoxicity of various doxorubicin (DOX) loaded UiO-68-N3-DNA conjugates has also 
been assessed against MDA-MB-231 cells by measurement of time-dependent apoptosis 
(IncuCyte® Red cytotoxicity assay) [98]. The empty MOFs induced less than 20% cell death 
after 42 h, while the DOX-loaded MOF functionalised with a pH-responsive cytosine-rich 
DNA sequence induced around 50% cell apoptosis for the same incubation time. Addition of 
the AS1411 aptamer, which binds to the nucleolin receptor that is overexpressed on the 
surface of cancer cells, to the doxorubicin-loaded MOF induced 100% cell death for the 
same incubation time, as a consequence of targeting. Surface functionalisation with Mg2+-
dependent DNAzyme subunits separated by ATP-aptamer sequences gave a MOF that did 
not induce cell death in both MFC-10A breast epithelial cells and MDA-MB-231 breast 
cancer cells. After DOX-loading, the MOF decreased proliferation of the breast cancer cells 
to ~70% after 3 days and ~60% after 5 days, as intracellular Mg2+ and ATP triggered DOX 
release, without affecting the growth of the healthy cells (Figures 24a-24c).  
 
 
 
Figure 24. Cytotoxicity (IncuCyte® Red apoptosis assay) after a) 3 days and b) 5 days of (i) control 
cells, (ii) empty UiO-68-N3-DNA conjugated with Mg
2+
 and ATP-responsive DNA sequences, and (iii) 
doxorubicin loaded analogues. Modified with permission from ref [98] copyright (2017) The Royal 
Society of Chemistry. c) Chemical structure of doxorubicin. d) Cell viability of MDA-MB-231 cells 
incubated with DOX@UiO-66-Py-PGA-PEG-F3, DOX@UiO-66-Py-PGA-PEG, and Py-PGA-PEG-F3. 
Modified with permission from ref [100] copyright (2017) American Chemical Society.  
 
In vitro tumour targeting using the F3 nucleolin targeting peptide was investigated by FACS 
with 89Zr-UiO-66-Py-PGA-PEG-F3 showing that uptake was higher in MDA-MB-231 triple-
negative breast cancer cells, which over express the nucleolin receptor (n+), compared to 
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L929 fibroblasts, which do not (n-) [100]. The empty MOF did not affect MDA-MB-231 cell 
growth in concentration range (0-50 µgmL-1), and the doxorubicin loaded analogue 
decreased MDA-MB-231 cell viability to a greater extent than an analogue without the F3 
peptide, as a consequence of enhanced MOF internalisation through targeting (Figure 24d).  
 
Drug delivery from Zr MOFs has also been combined with imaging in hybrid systems. Core-
shell iron oxide-MOF nanoparticles, Fe3O4@UiO-66-NH2 (core 150 nm; shell 2, 25, 50 nm), 
were synthesised through growth of UiO-66-NH2 on the surface of carboxylate capped Fe3O4 
[141]. The core-shell MOFs exhibited strong superparamagnetic behaviour, retaining the 
properties of the core iron oxide with only minor decrease in saturation magnetisation from 
69.7 emug-1 to 51.6 emug-1 as a consequence of the MOF coating, suggesting their use as 
optimal T2-contrast agents. Fe3O4@UiO-66-NH2 has a high transverse relaxivity (r2) of 255.9 
Mms-1, considerably higher than some clinical Fe-based T2-weighed contrast agents. The 
effect of empty and DOX-loaded Fe3O4@UiO-66-NH2 on HeLa cell proliferation was 
investigated using the MTT assay. While the empty MOF did not induce cytotoxicity even at 
concentrations of 0.5 mgmL-1, proliferation decreased by 60% upon 24 h incubation with 
DOX@Fe3O4@UiO-66-NH2. The MOF possessed similar anticancer activity to DOX when 
the incubation time was 24 h, but this was enhanced after 48 h. The loaded MOF also did 
not significantly affect proliferation of healthy mouse fibroblast 3T3 cells at concentrations up 
to 0.5 mgmL-1 of MOF. 
 
A number of protocols have been adapted to induce selective cytotoxicity of MOF-based 
drug delivery systems, including targeting, stimuli-responsive release mechanisms, and 
photodynamic agents, while retaining excellent biocompatibility and stability. There is great 
potential for combining these strategies into dual-mode (e.g. PDT combined with medicinal 
cargo) or theranostic (imaging and treatment) systems, with materials now being prepared 
with these applications in mind. It is also evident that examining endocytosis in detail – 
mechanisms, localisations, exocytosis, etc – gives mechanistic information to inform design 
of materials, as for certain drugs it seems that the endocytosis mechanism is more important 
than uptake efficiency. There are also a large number of in vitro experiments to assess 
compatibility with the immune system, which give important information prior to, and possibly 
in place of, early stage in vivo experiments. 
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7. In Vivo Studies of Zirconium MOFs 
 
Building on the large and varied in vitro studies in the previous section, a small number of 
important in vivo experiments with Zr MOFs have been reported, both for imaging and 
delivery of therapeutics (Table 7). One of the first studies involved zebrafish embryos, which 
are often used as models for vertebrate development, and screened a range of MOFs for in 
vivo toxicity [50]. Both nanoparticulate UiO-66 and UiO-67 were found to have low toxicity 
towards zebrafish embryos, with yolk sac edema the only observed morphological defects, 
which correlated well with in vitro experiments. The Zr MOFs were found to have the lowest 
toxicity of the range studied. 
 
Table 7. Examples of in vivo drug delivery from Zr MOFs. 
MOF 
Drug 
Loading 
Animal Therapy / Imaging Negative Effects Ref 
UiO-66 
UiO-66-NH2 
UiO-67 
- 
Zebrafish 
embryo 
- Yolk sac edema [50] 
Zr89UiO-66-Py-PGA-
PEG-F3 
DOX 
50% w/w 
Nude mice; 
MDA-MB-231 
tumour-bearing 
Tumour accumulation; 
PET imaging; 
Targeted DOX delivery 
to tumours 
Liver and spleen 
accumulation 
[100] 
UiO-PDT - Kunming mice 
Tumour accumulation; 
CT imaging 
- [142] 
ZnDTPP-I2@UiO-66 - Nude mice 
TTA-UC imaging of 
lymph nodes 
- [79] 
Mn-doped 
UiO-66-PEG 
- 
H22 tumour-
bearing ICR 
mice 
Tumour remission on 
MW irradiation 
Liver visceral index 
increase (200 mgkg
-1
) 
Temporary passive 
behaviour (160 mgkg
-1
) 
[96] 
UiO-66-NH2-FA-5-
FAM 
5-FU 
Up to 
26% w/w 
Tumour bearing 
athymic nude 
mice 
Tumour fluorescence; 
Apparent tumour 
shrinkage 
40% death after 28 days [94] 
DOX@ 
Fe3O4@UiO-66-NH2 
DOX 
Kunming mice; 
HeLa tumour 
bearing 
Tumour accumulation; 
MRI imaging; 
Tumour shrinkage 
- [141] 
 
A number of studies using mice have been reported. The distribution and clearance profile of 
89Zr-UiO-66 in nude mice up to 120 h post-injection was investigated in vivo [100]. The 
health of the mice was monitored after treatment of medium doses (10 mgkg-1) and high 
doses (50 mgkg-1) of UiO-66-Py-PGA-PEG, finding no side effects or acute, medium or 
chronic toxicity. Positron emission tomography (PET) scans of MDA-MB-231 tumours in 
tumour-bearing mice were taken at point times of 0.5, 2, 20, 24, 48, 72, 96 and 120 h. The 
circulation half-life of 89Zr-UiO-66-Py-PGA-PEG was determined through serial blood 
sampling and found to be 118.8 min, indicating that the PEG surface density might not be 
high enough to prolong circulation times. Uptake of 89Zr-UiO-66-Py-PGA-PEG-F3 in MDA-
MB-231 tumours-in mice was found to be higher at all time points than 89Zr-UiO-66-Py-PGA-
PEG as a consequence of the F3 targeting peptide (Figure 25). However, after a maximum 
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uptake around 2 h after injection, MOF accumulation in tumour tissue gradually decreases 
with time. The MOFs were found to be highly accumulated in the liver and spleen, with no 
major decrease over time. In order to study F3 targeting properties, the NMOFs were 
administered together with a nucleolin blocking dose (10 mgkg-1) five minutes before 89Zr-
UiO-66-Py-PGA-PEG-F3, causing tumour uptake reduction and thus confirming that 
targeting through F3 peptide is one of the reasons why tumour uptake is enhanced, while 
liver and spleen accumulation were not affected. The MOFs have slow clearance from the 
liver, while no radioactivity was found in the bone or kidney. Tumour-muscle contrast was 
found to be efficient and as high as 76.3 ± 3.9 at 2 h post-injection, and 19.6 ± 5.4 after 120 
h. In vivo targeted delivery of doxorubicin (DOX) from DOX@UiO-66-Py-PGA-PEG and 
DOX@UiO-66-Py-PGA-PEG-F3 was studied by ex vivo fluorescence imaging, showing a 4-
fold increase in the DOX signal in the tumour upon F3 peptide targeting.  
 
 
 
Figure 25. Coronal PET images of MDA-MB-231 tumour-bearing mice (tumour highlighted in dashed 
circle) after injection with a) 
89
Zr-UiO-66-Py-PGA-PEG and b) 
89
Zr-UiO-66-Py-PGA-PEG-F3. 
Quantitative region-of-interest analysis of the PET data showing time-activity curves in organs for 
89
Zr-
UiO-66-Py-PGA-PEG and b) 
89
Zr-UiO-66-Py-PGA-PEG-F3. Both show enhanced tumour uptake by 
the targeted MOF. Modified with permission from ref [100] copyright (2017) American Chemical 
Society. 
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UiO-PDT has been assessed as an in vivo contrast agent for tumour computed tomography 
(CT) imaging in mice [142]. The bodipy-modified UiO-66 was tested for in vivo toxicity in 
Kunming mice, with injection of concentrations of UiO-PDT up to 100 mgkg-1 resulting in no 
significant histological abnormalities across a range of vital organs. Analysis of serum 
biochemistry showed no hepatic or kidney problems and haematology showed no changes 
to blood parameters. CT imaging of tumours in Sprague-Dawley rats implanted with 
cancerous cells showed preferential accumulation of UiO-PDT in the tumours rather than in 
surrounding tissue and organs, with a maximum signal observed after 24 h. 
 
Pd(II)-TCPP@UiO-68 was demonstrated to be a promising candidate for in vivo TTA- 
upconversion-based imaging; the MOF was found to undergo triplet diffusion/migration in 
water upon laser excitation ( = 532 ± 10 nm) with a threshold at solar irradiation suggesting 
upconversion luminescence (UCL) saturation at low irradiation power [82]. The authors 
postulated that the highly ordered alignment of the immobilized annihilators (the anthracene-
based linkers) in the MOF offers efficient diffusion, significantly reducing the nonradioactive 
decay pathways and resulting in long UCL life time (1.6 ms), much higher than other 
reported systems (~100 µs). Pd(II)-TCPP@UiO-68 displayed no cytotoxicity to HeLa cells in 
the dark, while in vitro imaging showed an intense upconverted luminescence at  = 450 ± 
25 nm when excited at 532 nm. Due to these results, Pd(II)-TCPP@UiO-68 was further 
studied for in vivo imaging in nude mice. 10 minutes after subcutaneous injection, the control 
mouse, injected with blank saline, showed no TTA-UC response in the blue emission 
channel while the mouse treated with MOF exhibited strong upconversion fluorescence with 
high contrast imaging (signal to noise ratio ~45) under excitation ( = 532 nm, 20 mWcm-2). 
The authors performed real-time imaging of lymph nodes – known to be implicated in cancer 
metastasis – of nude mice injected in the footpad with the MOF in PBS. Imaging was 
performed under the excitation of a 532 nm laser at 5 mWcm-2. Immediately after injection, 
upconversion response was found to be distributed close to the site of injection, whilst after 
one hour upconversion fluorescence was located in the sentinel node with a signal to noise 
ratio of 31, which is a significant response considering the very low excitation power (Figures 
26a and 26b). Additionally, no histological abnormalities were observed in the lymph node, 
as determined by hematoxylin and eosin stains.   
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Figure 26. In vivo TTA-UC imaging ( = 532 nm, 5 mWcm
-2
) of lymph nodes of a nude mouse after 
footpaw injection (2 mgmL
-1
) of Pd(II)-TCPP@UiO-68 at a) 5 minutes, and b) 60 minutes after 
injection. Modified with permission from ref [82] copyright (2018) American Chemical Society. c) 
Decrease in tumour size in ICR mice with H22 tumour cells after intravenous injection (40 mgkg
-1
) of 
Mn-doped-UiO-66-PEG and controls followed by MW irradiation 6 h later (1.8 W, 5 min). d) Survival 
rates of mice after 20 days following different treatments. Modified with permission from ref [96] 
copyright (2018) American Chemical Society. 
 
The potential of Mn-doped@UiO-66-PEG for microwave dynamic therapy (MWDT) and 
microwave thermal therapy (MWTT) has been tested in vivo. Toxicity of the MOF towards 
ICR mice bearing H22 mouse hepatocellular tumour cells was evaluated after injection with 
different doses (120, 160, 200 mgkg-1) of MOF dispersed in aqueous NaCl [96]. White blood 
cells were analysed and were found to be in the normal range although statistical differences 
with the control group were found. The visceral index of the liver increased after injection at 
200 mgKg-1, indicating that higher doses of the MOF might affect the liver. Hence 160 mgKg-
1 was stated as the maximum tolerated dose, for which only passive behaviour and weight 
loss was observed in mice 24 h after injection, with no other abnormal behaviour, and the 
mice returned to normality after 48 h. Biodistribution was evaluated by ICP-OES, showing 
the highest Zr content in the tumour 6 h after administration, after which it decreases. Thus, 
MW irradiation (1.8 W, 5 min) at 6 h post-injection was chosen. Tumour temperature raised 
10 °C (comparison performed between MW group and group treated with MOF plus MW) as 
determined by infrared thermal imagining. Significant differences in tumour size 20 days 
post-injection were observed (Figures 26c and 26d). While administration of the MOF 
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without MW irradiation or MW irradiation on its own resulted in no decrease in tumour size, 
remission was notable after MOF treatment with MW irradiation, with the tumours almost 
completely destroyed. A control treated in which mice were treated with UiO-66 without Mn 
doping confirmed the MWTT and MWDT synergic effect. Although tumours could also reach 
a high temperature upon treatment with UiO-66 and MW irradiation, tumour recurrence was 
observed after 5 days, while it totally disappears for the Mn-doped@UiO-66-PEG; undoped 
Zr-MOFs only act as a MWTT agent, with a similar MW conversion to the Mn-doped 
analogue, but not as a MWDT agent, as they do not catalyse the formation of hydroxyl 
radicals.  
 
Tumour bearing athymic nude mice treated with 5-FU@UiO-66-NH2-FA-5-FAM did not have 
a good survival rate, as 28 days after treatment only three mice out of five were alive. 
Significant fluorescence was observed in the tumour and lungs after 12 h, but not in the liver 
or spleen, which is common with MOFs and other nanomaterials, suggesting either targeted 
tumour uptake or in vivo release of the fluorescent coating. Although tumour remission of the 
treated group compared to a PBS-only control was observed, the statistical significance is 
almost minimal due to the large standard deviations of tumour size of both groups. The 
authors attribute mice death to the inherent cytotoxicity of 5-fluorouracil and postulate that 5-
FU@UiO-66-NH2-FA-5-FAM could reduce its toxic effect [94]. 
 
The potential of Fe3O4@UiO-66-NH2 core-shell composites as magnetic resonance imaging 
(MRI) contrast agents was evaluated in vivo in Kunming mice [141]. Significant signal 
darkening was found in the liver 10 minutes post-injection, and in the tumour after one hour, 
continuing to increase to 9 h post-injection time, thus confirming accumulation in tumour 
tissue after prolonged times. Biodistribution and toxicology studies were performed in vivo to 
evaluate potential toxic effects, and thus T2-weighted images of Kunming mice were taken 
1, 7, 14, and 30 days after injection. Since no darkening effect was found in the urinary 
bladder, while high darkening with time-recovery signal was observed in the liver, 
Fe3O4@UiO-66-NH2 seems to be excreted from the liver rather than from the kidney. The 
biodistribution of the core-shell NPs was also determined ex vivo by ICP-MS determination 
of the iron and zirconium levels of the different digested organs in specimens after 1, 7, and 
30 days of injection. In concordance with the T2-weighted images, significant accumulation 
of Zr and Fe was found in the liver and spleen. The levels decreased with prolonged times, 
reaching similar levels to an untreated control after 30 days, although the iron content in the 
liver was slightly higher than the untreated mice after 30 days (Figure 27a). The body weight 
and growth of mice was found not to be affected, and blood analysis (Figure 27b) was 
consistent with the untreated control. In general, it was proven that Fe3O4@UiO-66-NH2 is 
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relatively safe for in vivo treatments. The anticancer therapeutic effect of the core-shell 
nanoparticles was also measured in vivo towards HeLa bearing tumour mice. While tumours 
in control mice grew quickly, mice treated with DOX@Fe3O4@UiO-66-NH2 showed a 4-fold 
decrease in tumour mass, which could be monitored in vivo through MRI (Figures 27c and 
27d). 
 
 
 
Figure 27. a) In vivo biodistribution of Fe from Fe3O4@UiO-66-NH2 in mice organs. b) Biochemistry of 
mouse blood after treatment with Fe3O4@UiO-66-NH2 (24 mgkg
-1
). Magnetic resonance images of 
tumours from HeLa tumour bearing mice after treatment with c) DOX@Fe3O4@UiO-66-NH2 compared 
to d) PBS, showing tumour shrinkage after treatment with the MOF. Modified with permission from ref 
[141] copyright (2016) The Royal Society of Chemistry. 
 
In vivo studies are important experiments in the development of MOF-based DDSs, giving 
information on adverse effects, biodistribution, and treatment efficiency [143]. There are, 
however, a number of in vitro experiments which can give similar information without 
resorting to early stage animal testing. The studies to date suggest tumour uptake of NMOFs 
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by the enhanced permeability and retention effect, but also accumulation in the liver and 
spleen, which is often a consequence of high macrophage recognition and uptake. 
Therefore, developing surface functionality that avoids macrophage recognition, while further 
enhancing cancer cell uptake through targeting units, might be an alternative to overcome 
accumulation in the body. Additionally, surface modifications that ensure adequate colloidal 
dispersion and minimal drug release under extracellular conditions, alongside fast surface 
detachment and consequent degradation under intracellular conditions, might be an 
alternative to overcome accumulation issues.  
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8. Conclusions 
 
In a relatively short time period a large volume of research has arisen examining Zr MOFs in 
drug delivery and other bioapplications. A number of factors have led to this rapid 
emergence, including the development of protocols for synthetic control over particle size 
and morphology, the amenability of Zr MOFs to postsynthetic modification, their high storage 
capacity for drug cargo, their excellent aqueous stability and colloidal dispersion, and their 
biocompatibility. The complexity of hybrid materials has also rapidly increased, with 
incorporation of targeting peptides, DNAzymes, and stimuli-responsive release mechanisms 
leading to in vitro assessment of imaging, drug delivery, and photodynamic therapy, as well 
as a burgeoning body of in vivo studies. The review has highlighted a number of strategies 
to enhance physical properties and therapeutic efficiencies; it is expected that many of these 
are orthogonal with one another and so combined in vivo targeted theranostic devices could 
be the next development in the field. As well as the large number of studies describing 
incorporation of primarily organic functionality, metal doping and hybrid nanoparticle devices 
are beginning to be used for imaging purposes. A number of metal ions can form the 
hexameric cluster that links most Zr MOFs, and so it is likely that doping of metals such 
lanthanides for MRI, for example into existing structures will be possible. The compatibility of 
Zr MOFs with biological entities suggests further bioapplications will also be possible, for 
example, the intracellular sensing of HClO by a redox-active UiO-68 derivative [144]. 
 
Furthermore, there are isostructural Hf variants of most Zr MOFs, and a number have been 
used in similar settings to their Zr MOF analogues. For example, both Zr and Hf analogues 
of UiO-66 have been assessed as contrast agents for computed tomography, with promising 
in vitro and in vivo results from UiO-66(Hf) that had been surface coated with silica and 
poly(ethylene glycol) [145]. Hf-based porphyrin [146] and chlorin [147] MOFs have been 
used for PDT, while Hf MOFs have been shown to act as radioenhancers, improving the 
efficacy of radiotherapy while concurrently delivering therapeutic cargo [148, 149]. With 
these latest innovations in mind, it is not unreasonable to foresee the use of so-called 
theranostic MOFs in the near future that (i) contain metals  that are active for imaging, (ii) are 
linked by ligands with activity for PDT or otherwise, (iii) are loaded with different types of 
therapeutic cargo, and (iv) are surface modified for targeting and biodistribution, enabled by 
the continuing development of orthogonal protocols for functionalisation and encapsulation 
alongside the desirable properties of Zr MOFs for bioapplications.  
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10. Abbreviations and Acronyms 
 
3T3   Mouse fibroblast cell line 
5-FAM  5-Carboxyfluorescein 
5-FU  5-Fluorouracil  
-CHC  -Cyanohydroxycinnamic acid 
A2780  Human ovarian carcinoma cell line 
A549   Human lung carcinoma cell line 
AcOH   Acetic acid  
AL   Alendronate  
ATP   Adenosine triphosphate  
B16F10  Mouse skin melanoma cell line 
BCDTE 1,2-bis(5-(4-carboxyphenyl)-2-methylthien-3-yl)cyclopent-1-ene 
BET  Brunauer-Emmett-Teller  
BDC  Benzenedicarboxylic acid  
Biot  Biotin  
BODIPY  Boron dipyrromethene  
BPDC  Biphenyldicarboxylic acid  
C26   Mouse colon carcinoma cell line 
cal  Calcein  
CF  Carboxyfluorescein 
CHCl3  Chloroform  
CM  Coordination modulation  
CP5  Decacarboxylato-pillar[5]arene 
CT  Computed tomography 
CT26   Murine colon carcinoma cell line 
CuAAC  Copper-catalysed azide-alkyne cycloaddition  
CytC   Cytochrome c protein  
DBCO  Dibenzylcyclooctyne  
DCA  Dichloroacetic acid 
DCFH-DA 2′,7′-dichlorodihydrofluorescein diacetate  
DDS  Drug delivery system  
DLS  Dynamic light scattering  
DMF  Dimethylformamide  
DNA  Deoxyribonucleic acid  
DOPA   1,2-dioleosyl-sn-glycero-3-phosphate  
DOPC  1,2-dioleoyl-sn-glycero-3-phospho-choline  
DOX   Doxorubicin  
DPBF  1,3-diphenylisobenzofuran 
DS  Diclofenac Sodium  
DTPP-I2 5,15-Di(4-methoxycarbonylphenyl)-10,20-bis(4-iodophenyl)-porphine 
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EDC  1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EPR  Enhanced permeability and retention  
EDX  Energy dispersive X-ray  
FA   Folic acid  
FACS  Fluorescence assisted cell sorting  
FITC  Fluorescein isothiocyanate 
FL83B  Mouse liver hepatocyte cell line 
FMN  Flavin mononucleotide  
FT-IR  Fourier transform infra-red  
FR  Folate receptor  
GFP  Green fluorescent protein 
H22  Mouse hepatocellular carcinoma cell line 
H460   Human lung carcinoma cell line 
HBG  HEPES buffered glucose  
HCl  Hydrochloric acid 
HEK293 Human embryonic kidney cell line 
HeLa   Human cervical cancer cell line 
Hep  Heparin 
HepG2  Human liver carcinoma cell line 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HL-7702  Human liver hepatocyte cell line 
I2-BDP  3-(2’,6’-Diiodo-1’,3’,5’,7’-tetramethyl-4’,4’-difluoro-4’-bora-3’a,4’a-diaza-s- 
  indacen-8’-yl) propanoic acid 
IC50   Half inhibitory concentration  
ICP-MS Inductively coupled plasma optical emission spectroscopy  
ICP-OES Inductively coupled plasma mass spectrometry 
ICR  Institute of Cancer Research 
L929   Mouse fibroblast cell line 
LD50  Median lethal dose 
MCF-7  Human breast carcinoma cell line 
MDA-MB-231 Triple negative human breast cancer cell line 
MDA-MB-468 Human breast cancer cell line 
MFC-10A  Human breast epithelial cell line  
MOF  Metal-organic framework  
MTS   (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-  
  sulfophenyl)-2H-tetrazolium)  
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
MRI  Magnetic resonance imaging  
MW  Microwave  
MWDT  Microwave dynamic therapy  
MWTT  Microwave termal therapy 
NHS   N-hydroxysuccinimide 
NIR  Near infrared 
NMOF  Nanoparticulate metal-organic framework  
NMR  Nuclear magnetic resonance  
NP  Nanoparticle 
PBLs   Phospholipid bilayers  
PBS   Phosphate buffered saline 
PC12  Rat neuroblastic pheochromocytoma cell line 
PCL-TPGS Poly(ε-caprolactone)-alpha tocopheryl polyethylene glycol 1000   
  succinate 
PDT  Photodynamic therapy  
PEG  Poly(ethylene glycol)  
PET  Positron emission tomography 
PNIPAM  Poly(N-isopropylacrylamide)  
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PolyLact  Poly-L-Lactide  
PS  Postsynthetically  
PSM   Postsynthetic modification  
PXRD  Powder X-ray diffraction 
Py-PGA-PEG poly(γ-glutamic acid)-pyrene(30%)-poly(ethylene glycol) 
ROS   Reactive oxygen species  
SBU  Secondary building unit  
SEM  Scanning electron microscopy  
SIM  Structured illumination microscopy 
siRNA  Small interfering ribonucleic acid 
SKOV-3  Human ovarian cancer cell line 
SLE  Surface ligand exchange  
SMMC-7721  Human hepatocellular carcinoma cell line 
SPAAC Strain-promoted azide-alkyne cycloaddition 
STEM   Scanning tunnelling electron microscopy  
TCPP  5,10,15,20-Tetrakis(4-carboxyphenyl)porphyrin 
TEA   Triethylamine  
TGA  Thermogravimetric analysis  
TPP-SH 5-(4-(S-ethylthiolester)thiocarbonylphenyl)-10,15,20-tris(4-chlorophenyl)- 
  porphyrin 
TTA-UC Triplet-triplet annihilation upconversion 
UCNPs  Upconverting nanoparticles  
UV-Vis  Ultraviolet-visible spectroscopy  
XPS   X-ray photoelectron spectroscopy  
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